



(43) International Publication Date
2 August 2012 (02.08.2012)

(10) International Publication Number
WO 2012/103235 A1

- (51) **International Patent Classification:**
C12N 5/095 (2010.01) *G01N 33/50* (2006.01)
- (21) **International Application Number:**
PCT/US2012/022575
- (22) **International Filing Date:**
25 January 2012 (25.01.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/436,068 25 January 2011 (25.01.2011) US
- (72) **Inventors; and**
- (71) **Applicants :** **KO, Minoru, S.H.** [US/US]; 10516 Willow Vista Way, Cockeysville, MD 21030 (US). **KO, Shigeru, B.H.** [JP/JP]; 13-1 Kitakasaya, Inuyama, Inuyama, Aichi, 484-0081 (JP).
- (74) **Agents:** **OTIS, Littlefield** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** ZSCAN4 AS A MARKER FOR PANCREATIC STEM CELLS AND PROGENITOR CELLS AND USE THEREOF

(57) **Abstract:** ZSCAN4, a gene expressed in ES cells and 2-cell stage embryos, has been previously shown to regulate telomere elongation and genome stability in mouse ES cells. It is disclosed herein that in the adult human pancreas, a small number of ZSCAN4-positive cells are present among cells located in the islets of Langerhans, acini, and ducts. These data disclosed herein indicate that expression of ZSCAN4 is a marker for rare stem/progenitor cells in adult human pancreas. Thus, provided herein is a method of isolating pancreatic stem cells or progenitor cell from a sample by detecting expression of ZSCAN4. Also provided is a method of treating diabetes by isolating ZSCAN4⁺ pancreatic stem cells or progenitor cells, expanding the cells in vitro and transplanted the expanded cells into the subject. The expanded ZSCAN4⁺ cells can optionally be differentiated into pancreatic β cells before transplanting the cells into the subject. Further provided is an in vivo method of expanding a population of pancreatic stem cells or progenitor cells in a subject by delivering a ZSCAN4 protein, a ZSCAN4 nucleic acid sequence, or an agent that increases expression of ZSCAN4 to the pancreas of the subject.



WO 2012/103235 A1

ZSCAN4 AS A MARKER FOR PANCREATIC STEM CELLS AND PROGENITOR CELLS AND USE THEREOF

FIELD

5 This disclosure relates to the identification of ZSCAN4-expressing stem cells and progenitor cells in human pancreas, the use of ZSCAN4 as a marker for pancreatic stem cells and progenitor cells, and the use of such pancreatic stem cells and progenitor cells for treating diabetes.

SUBMISSION OF SEQUENCE LISTING AS ASCII TEXT FILE

10 The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 699442000340SeqList.txt, date recorded: January 25, 2012, size: 52 KB).

BACKGROUND

 The Zscan4 gene was identified by expression profiling of all preimplantation
15 stages of mouse embryos using a large-scale cDNA sequencing project (Ko *et al.*, *Development* 127:1737-1749, 2000; Sharov *et al.*, *PLoS Biol* 1:E74, 2003) and DNA microarray analysis (Hamatani *et al.*, *Dev Cell* 6:117-131, 2004). In mice, Zscan4 consists of 6 paralog genes (Zscan4a to Zscan4f) and 3 pseudogenes (Zscan4-ps1 to Zscan4-ps3) clustered on an approximately 850 kb region of chromosome 7. Among
20 the six paralogs, the open reading frames of Zscan4c, Zscan4d, and Zscan4f encode a SCAN domain as well as all four zinc finger domains, suggesting their potential role as transcription factors. A high expression peak of Zscan4 marks the late 2-cell stage of mouse embryos. Zscan4 expression, normally below detection threshold in blastocysts, is reactivated *in vitro* in a small fraction of ES cells in culture. Although all six Zscan4
25 paralogs are expressed in ES cells, Zscan4c is the predominant paralog, whereas Zscan4d is the predominant paralog in 2-cell embryos (Falco *et al.*, *Dev Biol* 307:539-550, 2007; PCT Publication No. WO 2008/118957).

 It has previously been demonstrated that Zscan4 is associated with a unique transient state in undifferentiated ES cells in which other 2-cell embryo-specific genes
30 are activated. Zscan4 is essential for long-term maintenance of genomic integrity and

for mediating a regulated telomere recombination in normal undifferentiated ES cells (Zalzman *et al.*, *Nature* 464(7290):858-863, 2010).

The pancreas has been a focus of intensive research in regenerative medicine because type I diabetes could potentially be cured if insulin-producing pancreatic cells are supplemented. Thus, identifying progenitor cells that could give rise to endocrine and exocrine cells in the adult human pancreas is desirable. The existence of progenitor cells in pancreatic ducts has previously been speculated based on the observation that all pancreatic cells develop from progenitor cells that form duct-like structures in the embryonic pancreas (Oliver-Krasinski and Stoffers, *Genes Dev* 22:1998-2021, 2008). However, little is known about whether undifferentiated progenitor cells exist in pancreatic ducts or if differentiated cells can redifferentiate to other cells types (Aguayo-Mazzucato and Bonner-Weir, *Nat Rev Endocrinol* 6:139-148, 2010). One major hurdle to the identification of resident stem cells in the pancreas is that this tissue type that has a very low rate of spontaneous self-renewal, thus it is expected that the number of pancreatic stems cells, if any, is very low (Barker and Clevers, *Gastroenterology* 138:1681-1696, 2010). Another challenge to identifying resident stem cells is the lack of specific tissue stem cell markers, which has hampered the progress in identifying such a rare cell type in human pancreatic tissues.

20

SUMMARY

Disclosed herein is the finding that ZSCAN4 serves as a marker for rare stem/progenitor cells in adult human pancreas. Thus, provided herein is a method of isolating pancreatic stem cells or pancreatic progenitor cells, or both, from a sample, such as a pancreatic tissue sample. In some embodiments, the method includes detecting expression of ZSCAN4 in cells of the sample and isolating the cells that express ZSCAN4.

25

Also provided is a method of treating diabetes in a subject. In some embodiments, the method includes (i) isolating pancreatic stem cells or pancreatic

progenitor cells, wherein isolating the pancreatic stem cells or progenitor cells comprises detecting cells in pancreatic tissue that express ZSCAN4; (ii) expanding the isolated pancreatic stem cells or progenitor cells that express ZSCAN4 *in vitro*; and (iii) transplanting the expanded pancreatic stem cells or progenitor cells into the subject. In particular examples, the pancreatic stem cells or progenitor cells are isolated from the subject to be treated.

Further provided is an *in vivo* method of expanding a population of pancreatic stem cells or progenitor cells in a subject. In some embodiments, the method includes delivering to the pancreas of the subject a ZSCAN4 protein; a ZSCAN4 nucleic acid sequence; or an agent that increases expression of ZSCAN4 or the number of ZSCAN4+ cells.

The foregoing and other objects and features of the disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1H are a series of images showing immunolocalization of ZSCAN4 in human pancreas. (A) Existence of a ZSCAN4⁺ cell in the islet of Langerhans. Strong nuclear staining was observed in this cell. (B) ZSCAN4⁺ cells are located at the peripheral region of the islet. A weak cytoplasmic staining was evident in endocrine cells. ZSCAN4⁺ cells are also located in acinus (C) and in the duct (D). Oval-shaped cells ("pancreatic oval cells") are also positive for ZSCAN4 (E). An anti-mouse Zscan4 antibody (F and H) and anti-human ZSCAN4 antibody (G and H) stained identical cells in the human pancreas (oval-shaped cells). i, islet of Langerhans; a, acinus; d, duct.

FIGS. 2A-2N are a series of images showing immunolocalization of BMI1 and LGR5 in human pancreas. BMI1⁺ cells are located in the islet of Langerhans (A), in the duct (B), and in acinus (C). LGR5⁺ cells are also localized in the islet of Langerhans

(D), in the duct (E), and in acinus (F). Only a small number of cells are positive for BMI1 or LGR5, similar to the staining pattern of ZSCAN4 in FIG.1. Pancreatic oval cells between pancreatic acini are also positive for BMI1 and LGR5 (C and F). Double-immunofluorescent labeling of cells was performed in the islet of Langerhans (G-N).
 5 BMI1 and LGR5 mark identical cells in the islet (G-J). ZSCAN4 marks only a subset of LGR5 positive cells (K-N). d, duct; a, acinus; asterisk, oval cells; i, islet of Langerhans.

FIGS. 3A-3H are a series of images showing immunolocalization of insulin and LGR5 in a pancreatic islet (A-D). Insulin⁺ cells and LGR5⁺ cells are not co-localized.
 10 Immunolocalization of amylase and LGR5 in exocrine cells was performed (E-H). Amylase⁺ cells and LGR⁺ cells are not co-localized.

FIGS. 4A-4N are a series of images of human pancreas. (A-C) Immunolocalization of aquaporin 1 water channel (AQP1) in human pancreas. AQP1 is expressed in cells located from centroacinar cells (ca) to medium sized interlobular
 15 ducts. Both pancreatic stellate cells (black arrow) and oval cells (asterisk) are positive for AQP1. (D-G) A ZSCAN4⁺ cell in pancreatic duct is positive for AQP1. A rectangular-shaped ZSCAN4⁺ cell is AQP1 negative (asterisk). (H-K) BMI1⁺ cell is also positive for AQP1. BMI1⁺ cells are clearly distinguishable from neighboring cells by the DIC microscopy (H). (L-N) Localization of CD163⁺ cells. Most of the
 20 pancreatic stellate cells (arrow) and oval cells (asterisk) between acini are positive for CD163. A subset of pancreatic duct cells (M, between two black arrows) and basal membranes of pancreatic ducts (N) are also positive for CD163.

FIGS. 5A-5F are a series of images showing ZSCAN4 expression patterns in tissues taken from patients with chronic alcoholic pancreatitis and autoimmune
 25 pancreatitis. (A) A representative ZSCAN4-immunostaining of the pancreas from an unaffected individual (arrow, a ZSCAN4⁺ cell). (B) A representative ZSCAN4-immunostaining of the pancreas from a patient with chronic alcoholic pancreatitis. (C) A representative ZSCAN4-immunostaining of duct region of the pancreas from a

patient with autoimmune pancreatitis before corticosteroid therapy. ZSCAN4⁺ cells increase in tissues on chronic inflammation (arrows, ZSCAN4⁺ cells). (D) A representative ZSCAN4-immunostaining of acinar region of the pancreas from a patient with autoimmune pancreatitis before corticosteroid therapy. (E) A representative
 5 ZSCAN4-immunostaining of the pancreas from a patient with autoimmune pancreatitis 3 months after the initiation of corticosteroid treatment. A large number of ZSCAN4⁺ cells are seen in pancreatic ducts, the islet of Langerhans, and regenerated acini. (F) A representative ZSCAN4-immunostaining of the pancreas from a patient with autoimmune pancreatitis 1 year after corticosteroids under the maintenance
 10 corticosteroid therapy. Only a few ZSCAN4⁺ cells are seen here. a, acinus; d, ducts; i, islet of Langerhans.

FIGS. 6A-6L are a series of images showing immunolocalization of ZSCAN4⁺ cells in mouse and human pancreas. An anti-mouse Zscan4 antibody (in A, D, G, and J) and anti-human ZSCAN4 antibody (in B, E, H, and K) mark identical cells both in
 15 human (C) and mouse pancreas (in F, I, and L).

FIGS. 7A-7L are a series of images showing immunolocalization of pancreatic endocrine hormones and LGR5 in human pancreas. Shown is staining for glucagon (A-D), somatostatin (E-H), and ghrelin (I-L).

FIGS. 8A-8L are a series of images showing immunolocalization of endocrine
 20 hormones in human pancreas. Shown is staining for insulin (A-C), glucagon (D-F), somatostatin (G-I), and ghrelin (J-L). Endocrine hormone-positive cells are seen not only in pancreatic islets but also in pancreatic ducts (C, F, I, L), and pancreatic acini (B, E, H, K). a, acinus; d, duct.

FIGS. 9A-9F are a series of images showing immunolocalization of insulin and
 25 amylase in human pancreas. (A-C) Exocrine cells produce digestive enzyme amylase and endocrine cells in the islet of Langerhans produce insulin. These cells are mutually exclusive in the pancreas. (D-F) A small number of cells in pancreatic acini are double-positive for insulin and amylase (arrow).

FIGS. 10A-10K are a series of images showing immunolocalization of cystic fibrosis transmembrane conductance regulator (CFTR) in human pancreas. CFTR is expressed in the apical plasma membrane of cells in small pancreatic ducts from centroacinar cells (ca) to intralobular ducts (A). By contrast to AQP1, CFTR is not expressed in pancreatic stellate cells (arrow) (B). However, pancreatic oval cells express CFTR in its plasma membrane (C). (D-H) Double-staining of cells with an anti-CFTR and anti-LGR5 antibody. CFTR and LGR5 expression are mutually exclusive (G and K). a, acinus; ic, intercalated duct; asterisk indicates pancreatic oval cells.

FIG. 11 is a series of images showing immunohistochemical staining of mouse pancreatic tissue to detect expression of Zscan4, SSEA3, LGR5 and BMI1. Shown are tissue sections from control animals and animals with caerulein-induced pancreatitis (D1: 1 day after caerulein treatment; D4, 4 days after caerulein treatment).

SEQUENCE LISTING

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. In the accompanying sequence listing:

SEQ ID NOs: 1 and 2 are nucleotide and amino acid sequences of human ZSCAN4.

SEQ ID NOs: 3 and 4 are nucleotide and amino acid sequences of mouse Zscan4a.

SEQ ID NOs: 5 and 6 are nucleotide and amino acid sequences of mouse Zscan4b.

SEQ ID NOs: 7 and 8 are nucleotide and amino acid sequences of mouse Zscan4c.

SEQ ID NOs: 9 and 10 are nucleotide and amino acid sequences of mouse Zscan4d.

SEQ ID NOs: 11 and 12 are nucleotide and amino acid sequences of mouse Zscan4e.

5 **SEQ ID NOs: 13 and 14** are nucleotide and amino acid sequences of mouse Zscan4f.

SEQ ID NO: 15 is the nucleotide sequence of the Zscan4c promoter-Emerald expression vector (9396 bp). The starting nucleotide of the Zscan4c promoter sequence is 906 and the ending nucleotide is 4468.

10

DETAILED DESCRIPTION

I. Abbreviations

	AQP1	aquaporin 1
	BMI1	polycomb ring finger oncogene
15	CFTR	cystic fibrosis transmembrane conductance regulator
	ES	embryonic stem
	FACS	fluorescence-activated cell sorting
	iPS	induced pluripotent stem
	LGR5	leucine-rich repeat-containing G-protein-coupled receptor 5
20	SSEA3	stage-specific embryonic antigen-3

II. Terms and Methods

Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Benjamin
 25 Lewin, *Genes V*, published by Oxford University Press, 1994 (ISBN 0-19-854287-9);
 Kendrew *et al.* (eds.), *The Encyclopedia of Molecular Biology*, published by Blackwell
 Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), *Molecular*

Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).

In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:

5 **Administration:** To provide or give a subject a compound or composition, such as cells that express ZSCAN4, a ZSCAN4 protein or nucleic acid, or an agent that increases expression of ZSCAN4, by any effective route. An exemplary route of administration includes, but is not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, intravenous, intra-arterial or
10 intrapancreatic).

Adult stem cell: Undifferentiated cells found throughout the body after embryonic development that multiply by cell division to replenish dying cells and regenerate damaged tissues. Adult stem cells are also known as somatic stem cells.

Agent: Any protein, nucleic acid molecule, compound, small molecule, organic
15 compound, inorganic compound, or other molecule of interest. In some embodiments, the "agent" is an agent that increases expression of ZSCAN4. In particular examples, the agent is a nucleic acid molecule encoding ZSCAN4 or a retinoid.

Antibiotic resistance gene: Any gene from a microorganism that confers resistance to an antibiotic. In some embodiments, the antibiotic resistance gene confers
20 resistance to puromycin.

Antibody: A polypeptide ligand comprising at least a light chain or heavy chain immunoglobulin variable region which specifically recognizes and binds an epitope of an antigen. Antibodies are composed of a heavy and a light chain, each of which has a variable region, termed the variable heavy (V_H) region and the variable
25 light (V_L) region. Together, the V_H region and the V_L region are responsible for binding the antigen recognized by the antibody.

 Antibodies include intact immunoglobulins and the variants and portions of antibodies well known in the art, such as Fab fragments, Fab' fragments, $F(ab)_2$

fragments, single chain Fv proteins ("scFv"), and disulfide stabilized Fv proteins ("dsFv"). A scFv protein is a fusion protein in which a light chain variable region of an immunoglobulin and a heavy chain variable region of an immunoglobulin are bound by a linker, while in dsFvs, the chains have been mutated to introduce a disulfide bond to stabilize the association of the chains. The term also includes genetically engineered forms such as chimeric antibodies (for example, humanized murine antibodies) and heteroconjugate antibodies (such as, bispecific antibodies). See also, *Pierce Catalog and Handbook*, 1994-1995 (Pierce Chemical Co., Rockford, IL); Kuby, J., *Immunology*, 3rd Ed., W. H. Freeman & Co., New York, 1997.

Typically, a naturally occurring immunoglobulin has heavy (H) chains and light (L) chains interconnected by disulfide bonds. There are two types of light chain, lambda (λ) and kappa (κ). There are five main heavy chain classes (or isotypes) which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE.

Each heavy and light chain contains a constant region and a variable region (the regions are also known as "domains"). In combination, the heavy and the light chain variable regions specifically bind the antigen. Light and heavy chain variable regions contain a "framework" region interrupted by three hypervariable regions, also called "complementarity-determining regions" or "CDRs." The extent of the framework region and CDRs has been defined (see, Kabat *et al.*, *Sequences of Proteins of Immunological Interest*, U.S. Department of Health and Human Services, 1991). The Kabat database is now maintained online. The sequences of the framework regions of different light or heavy chains are relatively conserved within a species, such as humans. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three-dimensional space.

References to "V_H" or "VH" refer to the variable region of an immunoglobulin heavy chain, including that of an Fv, scFv, dsFv or Fab. References to "V_L" or "VL"

refer to the variable region of an immunoglobulin light chain, including that of an Fv, scFv, dsFv or Fab.

A “monoclonal antibody” is an antibody produced by a single clone of B lymphocytes or by a cell into which the light and heavy chain genes of a single antibody have been transfected. Monoclonal antibodies are produced by methods known to those of skill in the art, for instance by making hybrid antibody-forming cells from a fusion of myeloma cells with immune spleen cells. Monoclonal antibodies include humanized monoclonal antibodies. As used herein “monoclonal antibodies” further includes antigen-binding fragments, such as Fv, scFv, dsFv or Fab fragments.

A “chimeric antibody” has framework residues from one species, such as human, and CDRs (which generally confer antigen binding) from another species, such as a murine antibody.

A “humanized” immunoglobulin is an immunoglobulin including a human framework region and one or more CDRs from a non-human (for example a mouse, rat, or synthetic) immunoglobulin. The non-human immunoglobulin providing the CDRs is termed a “donor,” and the human immunoglobulin providing the framework is termed an “acceptor.” In one embodiment, all the CDRs are from the donor immunoglobulin in a humanized immunoglobulin. Constant regions need not be present, but if they are, they must be substantially identical to human immunoglobulin constant regions, *i.e.*, at least about 85-90%, such as about 95% or more identical. Hence, all parts of a humanized immunoglobulin, except possibly the CDRs, are substantially identical to corresponding parts of natural human immunoglobulin sequences. A “humanized antibody” is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. A humanized antibody binds to the same antigen as the donor antibody that provides the CDRs. The acceptor framework of a humanized immunoglobulin or antibody may have a limited number of substitutions by amino acids taken from the donor framework. Humanized or other monoclonal antibodies can have additional conservative amino acid substitutions which have substantially no effect on

antigen binding or other immunoglobulin functions. Humanized immunoglobulins can be constructed by means of genetic engineering (see for example, U.S. Patent No. 5,585,089).

5 A “human” antibody (also called a “fully human” antibody) is an antibody that includes human framework regions and all of the CDRs from a human immunoglobulin. In one example, the framework and the CDRs are from the same originating human heavy and/or light chain amino acid sequence. However, frameworks from one human antibody can be engineered to include CDRs from a different human antibody. All parts of a human immunoglobulin are substantially identical to corresponding parts of
10 natural human immunoglobulin sequences

BMI1 (polycomb ring finger oncogene): A known tissue stem cell marker. BMI1 is necessary for efficient self-renewing cell divisions of adult mouse hematopoietic stem cells (Raaphorst, *Trends Immunol* 24:522-524, 2003). A single BMI1-expressing cell has been shown to form all the cell lineages in the intestinal
15 epithelium (Ootani *et al.*, *Nat Med* 15:701-706, 2009) and BMI1-lineage tracing has identified self-renewing pancreatic acinar cells capable of pancreatic organ homeostasis (Sangiorgi and Capecchi, *Proc Natl Acad Sci USA* 106:7101-7106, 2009).

Contacting: Placement in direct physical association; includes both in solid and liquid form.

20 **Co-expressed:** In the context of the present disclosure, genes that are “co-expressed” with ZSCAN4 are genes that exhibit a similar expression pattern as ZSCAN4 during embryonic development, in ES cells, and/or in tissue stem cells, such as pancreatic stem cells or progenitor cells. A number of genes that are co-expressed with ZSCAN4 have been previously described, including AF067063, Tcstv1/3, Tho4,
25 Arginase II, BC061212 and Gm428, Eif1a, EG668777 and Pif1 (see PCT Publication No. WO 2008/118957, which is herein incorporated by reference). In addition, it is disclosed herein (see Example 3) that SSEA3 is co-expressed with ZSCAN4 in

pancreatic cells. In particular embodiments disclosed herein, the gene co-expressed with ZSCAN4 is SSEA3 or Tctv1/3.

Degenerate variant: A polynucleotide encoding a polypeptide, such as a ZSCAN4 polypeptide, that includes a sequence that is degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included as long as the amino acid sequence of the polypeptide encoded by the nucleotide sequence is unchanged.

Detectable label: A detectable compound or composition that is conjugated directly or indirectly to another molecule, such as an antibody or a protein, to facilitate detection of that molecule. Specific, non-limiting examples of detectable labels include fluorescent tags, enzymatic linkages, and radioactive isotopes. Various methods of labeling polypeptides and other molecules are known in the art and may be used. Examples of detectable labels for polypeptides include, but are not limited to, the following: radioisotopes or radionucleotides (such as ^{35}S or ^{131}I), fluorescent labels (such as fluorescein isothiocyanate (FITC), rhodamine, lanthanide phosphors), enzymatic labels (such as horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase), chemiluminescent markers, chromophores (such as horseradish peroxidase or alkaline phosphatase), biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (such as a leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), or magnetic agents, such as gadolinium chelates.

Diabetes: A disease caused by a relative or absolute lack of insulin leading to uncontrolled carbohydrate metabolism. As used herein, "diabetes" refers to diabetes mellitus. Type 1 diabetes (sometimes referred to as "insulin dependent diabetes" or "juvenile onset diabetes") is an autoimmune disease characterized by destruction of the pancreatic β cells that leads to a total or near total lack of insulin. In diabetes type 2

(sometimes referred to as “non-insulin dependent diabetes” or “adult onset diabetes”), the body does not respond to insulin, though it is present.

Symptoms of diabetes include: excessive thirst (polydipsia); frequent urination (polyuria); extreme hunger or constant eating (polyphagia); unexplained weight loss; 5 presence of glucose in the urine (glycosuria); tiredness or fatigue; changes in vision; numbness or tingling in the extremities (hands, feet); slow-healing wounds or sores; and abnormally high frequency of infection. Diabetes may be clinically diagnosed by a fasting plasma glucose (FPG) concentration of greater than or equal to 7.0 mmol/L (126 mg/dL), or a plasma glucose concentration of greater than or equal to 11.1 mmol/L (200 10 mg/dL) at about two hours after an oral glucose tolerance test (OGTT) with a 75 g load. A more detailed description of diabetes may be found in *Cecil Textbook of Medicine*, J.B. Wyngaarden, *et al.*, eds. (W.B. Saunders Co., Philadelphia, 1992, 19th ed.).

Differentiation: Refers to the process by which a cell develops into a specific type of cell (for example, muscle cell, pancreatic cell, skin cell etc.). As a cell becomes 15 more differentiated, the cell loses potency, or the ability to become multiple different cell types.

Encapsulated: As used herein, a molecule (such as a nucleic acid or polypeptide) or cell “encapsulated” in a nanoparticle refers to a molecule or cell that is either contained within the nanoparticle or attached to the surface of the nanoparticle, or 20 a combination thereof.

Fluorescent protein: A genetically-encoded protein that exhibits fluorescence when exposed to a particular wavelength of light. A broad range of fluorescent protein genetic variants have been developed that feature fluorescence emission spectral profiles spanning almost the entire visible light spectrum. Examples include anthozoan 25 fluorescent proteins, green fluorescent protein (GFP) (which exhibits green fluorescence when exposed to blue light), as well as mutants thereof such as EGFP, blue fluorescent protein (EBFP, EBFP2, Azurite, mKalamal, which except for mKalamal contain a Y66H substitution.), cyan fluorescent protein (ECFP, Cerulean, CyPet, which include a

Y66W substitution), and yellow fluorescent protein derivatives (YFP, Citrine, Venus, YPet, which include a T203Y substitution). Other particular examples include Emerald Green Fluorescent Protein (EmGFP) and Strawberry. For an overview, see Shaner *et al.*, *Nat. Methods* 2(12):905-909, 2005.

5 **Fluorophore:** A chemical compound, which when excited by exposure to a particular wavelength of light, emits light (*i.e.*, fluoresces), for example at a different wavelength.

Examples of fluorophores that may be used in the methods disclosed herein are provided in U.S. Patent No. 5,866,366 to Nazarenko *et al.*: 4-acetamido-4'-
 10 isothiocyanatostilbene-2,2'-disulfonic acid, acridine and derivatives such as acridine and acridine isothiocyanate, 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS), 4-amino-N-[3-vinylsulfonyl]phenyl]naphthalimide-3,5 disulfonate (Lucifer Yellow VS), N-(4-anilino-1-naphthyl)maleimide, anthranilamide, Brilliant Yellow, coumarin and derivatives such as coumarin, 7-amino-4-methylcoumarin (AMC, Coumarin 120),
 15 7-amino-4-trifluoromethylcoumarin (Coumarin 151); cyanosine; 4',6-diaminidino-2-phenylindole (DAPI); 5', 5''-dibromopyrogallol-sulfonephthalein (Bromopyrogallol Red); 7-diethylamino-3-(4'-isothiocyanatophenyl)-4-methylcoumarin; diethylenetriamine pentaacetate; 4,4'-diisothiocyanatodihydro-stilbene-2,2'-disulfonic acid; 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid; 5-[dimethylamino]naphthalene-
 20 1-sulfonyl chloride (DNS, dansyl chloride); 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL); 4-dimethylaminophenylazophenyl-4'-isothiocyanate (DABITC); eosin and derivatives such as eosin and eosin isothiocyanate; erythrosin and derivatives such as erythrosin B and erythrosin isothiocyanate; ethidium; fluorescein and derivatives such as 5-carboxyfluorescein (FAM), 5-(4,6-dichlorotriazin-2-yl)aminofluorescein
 25 (DTAF), 2'7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein (JOE), fluorescein, fluorescein isothiocyanate (FITC), and QFITC (XRITC); fluorescamine; IR144; IR1446; Malachite Green isothiocyanate; 4-methylumbelliferone; ortho cresolphthalein; o-nitrotyrosine; pararosaniline; Phenol Red; B-phycoerythrin; R-phycoerythrin; o-

phthaldialdehyde; pyrene and derivatives such as pyrene, pyrene butyrate and succinimidyl 1-pyrene butyrate; Reactive Red 4 (Cibacron .RTM. Brilliant Red 3B-A); rhodamine and derivatives such as 6-carboxy-X-rhodamine (ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride, rhodamine (Rhod),
5 rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine 101 and sulfonyl chloride derivative of sulforhodamine 101 (Texas Red); N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA); tetramethyl rhodamine; tetramethyl rhodamine isothiocyanate (TRITC); riboflavin; rosolic acid and terbium chelate derivatives. Other suitable fluorophores include thiol-reactive europium
10 chelates which emit at approximately 617 nm (Heyduk and Heyduk, *Analyt. Biochem.* 248:216-27, 1997; *J. Biol. Chem.* 274:3315-22, 1999). Other suitable fluorophores include GFP, Lissamine™, diethylaminocoumarin, fluorescein chlorotriazinyl, naphthofluorescein, 4,7-dichlororhodamine and xanthene (as described in U.S. Patent No. 5,800,996 to Lee *et al.*) and derivatives thereof. Other fluorophores known to those
15 skilled in the art may also be used, for example those available from Molecular Probes (Eugene, OR).

Heterologous: A heterologous polypeptide or polynucleotide refers to a polypeptide or polynucleotide derived from a different source or species.

Host cell: A cell in which a vector can be propagated and its DNA expressed.
20 The cell may be prokaryotic or eukaryotic. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell" is used.

Isolated: An isolated nucleic acid, protein or cell has been substantially
25 separated or purified away from other components with which the nucleic acid, protein or cell naturally occurs. Thus an "isolated" nucleic acid or protein encompasses nucleic acids or proteins purified by standard biochemical purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell

as well as chemically synthesized nucleic acids and proteins. Similarly, “isolated” cells, such as those expressing ZSCAN4, have been substantially separated away from other cell types (such as cells that don’t express ZSCAN4). In the context of the present disclosure, “isolated” does not require 100% purity of the nucleic acid, protein or cell,
5 but encompasses nucleic acids, proteins and cells that are at least 70%, at least 80%, at least 90%, or at least 95% pure.

LGR5 (leucine-rich repeat-containing G-protein-coupled receptor 5): A stem cell marker of the intestinal epithelium and the hair follicle. The LGR5 protein is expressed in several organs (Barker and Clevers, *Gastroenterology* 138:1681-1696,
10 2010) and genetic marking of LGR5⁺ cells has identified this membrane protein as a marker for intestinal and skin tissue stem cells in mice (Barker *et al.*, *Nature* 449:1003-1007, 2007; Snippert *et al.*, *Science* 327:1385-1389, 2010). LGR5 is also known to play a role Wnt signaling. LGR5 sequences are publically available. For example, GenBank Accession Nos. NM_003667 and NP_003658 are human mRNA and protein
15 sequences of LGR5. The NCBI Gene ID for human LGR5 is 8549.

Multipotent cell: Refers to a cell that can form multiple cell lineages, but not all cell lineages.

Nanoparticle: A particle less than about 1000 nanometers (nm) in diameter. Exemplary nanoparticles for use with the methods provided herein are made of
20 biocompatible and biodegradable polymeric materials. In some embodiments, the nanoparticles are PLGA nanoparticles. As used herein, a “polymeric nanoparticle” is a nanoparticle made up of repeating subunits of a particular substance or substances. “Poly(lactic acid) nanoparticles” are nanoparticles having repeated lactic acid subunits. Similarly, “poly(glycolic acid) nanoparticles” are nanoparticles having repeated
25 glycolic acid subunits.

Operably linked: A first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is

operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked nucleic acid sequences are contiguous and where necessary to join two protein coding regions, in the same reading frame.

5 **Pancreas:** A nodular organ in the abdomen that contains a mixture of endocrine glands and exocrine glands. The small endocrine portion consists of the islets of Langerhans secreting a number of hormones into the blood stream. The large exocrine portion is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the duodenum.

10 **Pancreatic beta cell (or β cell):** A type of cell in the pancreas found in the islets of Langerhans. Beta cells produce and release insulin, which controls the level of glucose in the blood.

Pharmaceutically acceptable carriers: The pharmaceutically acceptable carriers of use are conventional. *Remington's Pharmaceutical Sciences*, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the Zscan4 proteins, Zscan4 nucleic acid molecules, or cells herein disclosed.

 In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example, sodium acetate or sorbitan monolaurate.

Pharmaceutical agent: A chemical compound, small molecule, cell or other composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject or a cell. "Incubating" includes a sufficient amount of time for a drug to interact with a cell. "Contacting" includes incubating a drug in solid or in liquid form with a cell.

Pluripotent cell: A cell that can form all of an organism's cell lineages (endoderm, mesoderm and ectoderm), including germ cells, but cannot form an entire organisms autonomously.

Polynucleotide: A nucleic acid sequence (such as a linear sequence) of at least six nucleotides, such as at least 12, at least 20, at least 30, at least 50, at least 100, at least 1000, or at least 10,000 nucleotides. Therefore, a polynucleotide includes oligonucleotides, and also gene sequences found in chromosomes. An "oligonucleotide" is a plurality of joined nucleotides joined by native phosphodiester bonds. An oligonucleotide is a polynucleotide of between 6 and 300 nucleotides in length. An oligonucleotide analog refers to moieties that function similarly to oligonucleotides but have non-naturally occurring portions. For example, oligonucleotide analogs can contain non-naturally occurring portions, such as altered sugar moieties or inter-sugar linkages, such as a phosphorothioate oligodeoxynucleotide. Functional analogs of naturally occurring polynucleotides can bind to RNA or DNA, and include peptide nucleic acid (PNA) molecules.

Polypeptide: A polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used, the L-isomers being preferred. The terms "polypeptide" or "protein" as used herein are intended to encompass any amino acid sequence and include modified sequences such as glycoproteins. The term "polypeptide" is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced.

The term “polypeptide fragment” refers to a portion of a polypeptide which exhibits at least one useful epitope. The term “functional fragments of a polypeptide” refers to all fragments of a polypeptide that retain an activity of the polypeptide, such as a ZSCAN4. Biologically functional fragments, for example, can vary in size from a
 5 polypeptide fragment as small as an epitope capable of binding an antibody molecule to a large polypeptide capable of participating in the characteristic induction or programming of phenotypic changes within a cell, including affecting cell proliferation or differentiation. Thus, smaller peptides containing the biological activity of ZSCAN4, or conservative variants of ZSCAN4, are thus included as being of use.

10 The term “substantially purified polypeptide” as used herein refers to a polypeptide which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. In one embodiment, the polypeptide is at least 50%, for example at least 80% free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. In another embodiment, the polypeptide
 15 is at least 90% free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. In yet another embodiment, the polypeptide is at least 95% free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.

Conservative substitutions replace one amino acid with another amino acid that
 20 is similar in size, hydrophobicity, etc. Examples of conservative substitutions that can be made to a native ZSCAN4 protein (such as SEQ ID NO: 2) are shown below:

	Original Residue	Conservative Substitutions
	Ala	Ser
	Arg	Lys
25	Asn	Gln, His
	Asp	Glu
	Cys	Ser
	Gln	Asn
	Glu	Asp
30	His	Asn; Gln
	Ile	Leu, Val

	Leu	Ile; Val
	Lys	Arg; Gln; Glu
	Met	Leu; Ile
	Phe	Met; Leu; Tyr
5	Ser	Thr
	Thr	Ser
	Trp	Tyr
	Tyr	Trp; Phe
	Val	Ile; Leu

10

Variations in the cDNA sequence that result in amino acid changes, whether conservative or not, should be minimized in order to preserve the functional and immunologic identity of the encoded protein. Thus, in several non-limiting examples, a ZSCAN4 polypeptide, or other polypeptides disclosed herein, includes at most two, at most five, at most ten, at most twenty, or at most fifty conservative substitutions. The immunologic identity of the protein may be assessed by determining whether it is recognized by an antibody; a variant that is recognized by such an antibody is immunologically conserved. Variant amino acid sequences may be, for example, at least 80%, 90% or even 95% or 98% identical to the native amino acid sequence (such as a native ZSCAN4 sequence).

20

Progenitor cells: Oligopotent or unipotent cells that differentiate into a specific type of cell or cell lineage. Progenitor cells are similar to stem cells but are more differentiated and exhibit limited self renewal.

Promoter: Nucleic acid control sequences which direct transcription of a nucleic acid. A promoter includes necessary nucleic acid sequences near the start site of transcription. A promoter also optionally includes distal enhancer or repressor elements. A “constitutive promoter” is a promoter that is continuously active and is not subject to regulation by external signals or molecules. In contrast, the activity of an “inducible promoter” is regulated by an external signal or molecule (for example, a transcription factor).

30

Reporter gene: A gene operably linked to another gene or nucleic acid sequence of interest (such as a promoter sequence). Reporter genes are used to determine whether the gene or nucleic acid of interest is expressed in a cell or has been activated in a cell. Reporter genes typically have easily identifiable characteristics, such as fluorescence, or easily assayed products, such as an enzyme. Reporter genes can also confer antibiotic resistance to a host cell. Exemplary reporter genes include fluorescent and luminescent proteins (such as green fluorescent protein (GFP) and the red fluorescent protein from the gene dsRed), the enzyme luciferase (which catalyzes a reaction with luciferin to produce light), the lacZ gene (which encodes the protein β -galactosidase, which causes cells expressing the gene to appear blue when grown on a medium that contains the substrate analog X-gal), and the chloramphenicol acetyltransferase (CAT) gene (which confers resistance to the antibiotic chloramphenicol). In one embodiment, the reporter gene encodes the fluorescent protein Emerald. In another embodiment, the reporter gene encodes the fluorescent protein Strawberry.

Retinoids: A class of chemical compounds that are related chemically to vitamin A. Retinoids are used in medicine, primarily due to the way they regulate epithelial cell growth. Retinoids have many important and diverse functions throughout the body including roles in vision, regulation of cell proliferation and differentiation, growth of bone tissue, immune function, and activation of tumor suppressor genes. Examples of retinoids include, but are not limited to, all-trans retinoic acid (atRA), 9-cis retinoic acid (9-cis RA), 13-cis RA and vitamin A (retinol).

Sample: A biological specimen containing genomic DNA, RNA (including mRNA), protein, cells, tissue, or combinations thereof, obtained from a subject. Examples include, but are not limited to, peripheral blood, urine, saliva, cerebrospinal fluid, tissue biopsy (such as pancreatic tissue), surgical specimen, and autopsy material. In one example the sample is a human pancreatic tissue sample.

Selectable marker: Refers to a gene that is introduced into a cell that confers a trait that allows for selection or isolation of the cell. Selectable markers include, for example, antibiotic resistance genes.

Sequence identity/similarity: The identity/similarity between two or more
5 nucleic acid sequences, or two or more amino acid sequences, is expressed in terms of the identity or similarity between the sequences. Sequence identity can be measured in terms of percentage identity; the higher the percentage, the more identical the sequences are. Sequence similarity can be measured in terms of percentage similarity (which takes into account conservative amino acid substitutions); the higher the percentage, the more
10 similar the sequences are. Homologs or orthologs of nucleic acid or amino acid sequences possess a relatively high degree of sequence identity/similarity when aligned using standard methods.

Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith & Waterman, *Adv. Appl. Math.* 2:482, 1981; Needleman & Wunsch, *J. Mol. Biol.* 48:443, 1970; Pearson &
15 Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444, 1988; Higgins & Sharp, *Gene*, 73:237-44, 1988; Higgins & Sharp, *CABIOS* 5:151-3, 1989; Corpet *et al.*, *Nuc. Acids Res.* 16:10881-90, 1988; Huang *et al.* *Computer Appls. in the Biosciences* 8, 155-65, 1992; and Pearson *et al.*, *Meth. Mol. Bio.* 24:307-31, 1994. Altschul *et al.*, *J. Mol. Biol.* 215:403-10, 1990,
20 presents a detailed consideration of sequence alignment methods and homology calculations.

The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul *et al.*, *J. Mol. Biol.* 215:403-10, 1990) is available from several sources, including the National Center for Biological Information (NCBI, National Library of Medicine, Building 38A, Room
25 8N805, Bethesda, MD 20894) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. Additional information can be found at the NCBI web site.

BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. If the two compared sequences share homology, then the designated output file will present those regions of homology as aligned sequences. If the two compared sequences do not share homology, then the designated output file will not present aligned sequences.

One of skill in the art will appreciate that the particular sequence identity ranges are provided for guidance only; it is possible that strongly significant homologs could be obtained that fall outside the ranges provided.

SSEA3 (stage-specific embryonic antigen-3): A molecule that was originally identified by monoclonal antibodies recognizing carbohydrate epitopes. SSEA3 is a known stem cell marker, especially for human pluripotent stem cells (Shevinsky *et al.*, *Cell* 30(3):697-705, 1982; Kannagi *et al.*, *EMBO J* 2(12):2355-2361, 1983; Kannagi *et al.*, *J Biol Chem* 258(14):8934-8942, 1983).

Stem cell: A cell having the unique capacity to produce unaltered daughter cells (self-renewal; cell division produces at least one daughter cell that is identical to the parent cell) and to give rise to specialized cell types (potency). Stem cells include, but are not limited to, ES cells, EG cells, GS cells, MAPCs, maGSCs, USSCs and adult stem cells. In one embodiment, stem cells can generate a fully differentiated functional cell of more than one given cell type. The role of stem cells *in vivo* is to replace cells that are destroyed during the normal life of an animal. Generally, stem cells can divide without limit. After division, the stem cell may remain as a stem cell, become a precursor cell, or proceed to terminal differentiation. A precursor cell is a cell that can generate a fully differentiated functional cell of at least one given cell type. Generally, precursor cells can divide. After division, a precursor cell can remain a precursor cell, or may proceed to terminal differentiation.

Subject: Living multi-cellular vertebrate organisms, a category that includes human and non-human mammals.

Tcstv1/3 (two-cell stage, variable group, members 1 and 3): A gene that has previously been shown to co-express with ZSCAN4 (PCT Publication No. WO 2008/118957). Tcstv1 and Tcstv3 are splice variants.

Therapeutic amount: An amount of a therapeutic agent sufficient to achieve the intended purpose. For example, a therapeutic amount of ZSCAN4⁺ pancreatic stem cells or progenitor cells is an amount sufficient to reduce a disorder or symptoms of a disorder that can benefit from such therapy, such as diabetes. A therapeutic amount may in some examples not treat the disorder or symptoms 100%. However, a decrease in any known feature or symptom of a disorder that can benefit from administration of the therapeutic agent, such as a decrease of at least 10%, at least 15%, at least 25%, at least 30%, at least 50%, at least 60%, at least 70%, at least 75%, at least 85%, at least 95%, or greater, can be therapeutic. The therapeutic amount of a given therapeutic agent will vary with factors such as the nature of the agent, the route of administration, the size and species of the animal to receive the therapeutic agent, and the purpose of the administration. The therapeutic amount in each individual case can be determined empirically without undue experimentation by a skilled artisan according to established methods in the art.

Totipotent cell: Refers to a cell that can form an entire organism autonomously. Only a fertilized egg (oocyte) possesses this ability (stem cells do not).

Transfecting or transfection: Refers to the process of introducing nucleic acid into a cell or tissue. Transfection can be achieved by any one of a number of methods, such as, but not limited to, liposomal-mediated transfection, electroporation and injection.

Transplanting: Refers to the process of grafting an organ, tissue or cells into a subject.

Vector: A nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication (DNA sequences that

participate in initiating DNA synthesis). For example, an expression vector contains the necessary regulatory sequences to allow transcription and translation of inserted gene or genes. A vector may also include one or more selectable marker genes and other genetic elements known in the art. Vectors include, for example, virus vectors and
5 plasmid vectors.

ZSCAN4: A group of genes that have previously identified as exhibiting 2-cell-specific expression and ES cell-specific expression (PCT Publication No. WO 2008/118957) and have been shown to promote telomere elongation and genome stability (Zalzman *et al.*, *Nature* 464(7290):858-863, 2010). In the context of the
10 present disclosure, "ZSCAN4" includes both human ZSCAN4 and mouse Zscan4. In the mouse, the term "Zscan4" refers to a collection of genes including three pseudogenes (Zscan1-ps1, Zscan4-ps2 and Zscan4-ps3) and six expressed genes (Zscan4a, Zscan4b, Zscan4c, Zscan4d, Zscan4e and Zscan4f). ZSCAN4 refers to ZSCAN4 polypeptides and ZSCAN4 polynucleotides encoding the ZSCAN4
15 polypeptides. Exemplary sequences are provided herein.

Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms "a," "an," and "the" include plural referents
20 unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. Hence "comprising A or B" means including A, or B, or A and B. It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.
25 Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein, including GenBank accession numbers, are incorporated by reference

in their entirety. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

5 *III. Overview of Several Embodiments*

The lack of appropriate markers has prevented the identification and isolation of stem cells and progenitor cells in the adult pancreas. It has previously been disclosed that Zscan4, a gene intermittently expressed in murine embryonic stem (ES) cells, regulates telomere elongation and genome stability in these cells. It is disclosed herein
10 that in the adult human pancreas, a small number of ZSCAN4-positive cells are present among cells located in the islets of Langerhans, acini, and ducts. It was also determined that ZSCAN4 is expressed in some of the oval-shaped cells located in the interstitium between acini, where pancreatic stellate cells are also located. In many cases, these ZSCAN4-positive cells were also positive for other tissue stem cell markers such as
15 BMI1 and LGR5. Furthermore, the number of ZSCAN4-positive cells dramatically increased in patients with chronic pancreatitis, especially in the pancreatic tissues actively regenerating after corticosteroid treatment. However, a year after the treatment, the number of ZSCAN4-positive cells returned to very low levels - comparable to that of the unaffected pancreas. The data disclosed herein indicate that
20 the expression of ZSCAN4 serves as a biomarker for rare stem/progenitor cells in adult human pancreas.

Accordingly, provided herein is a method of isolating pancreatic stem cells or pancreatic progenitor cells, or both, from a sample, such as a pancreatic tissue sample. In some embodiments, the method includes detecting expression of ZSCAN4 in cells of
25 the sample and isolating the cells that express ZSCAN4.

Also provided is a method of treating a subject with a disease or disorder of the pancreas. The disease or disorder of the pancreas can be associated with the endocrine function of the pancreas or the exocrine function of the pancreas. In some cases, the

disease or disorder associated with the endocrine function of the pancreas is diabetes.

Thus, provided herein is a method of treating diabetes in a subject. In some embodiments, the method includes (i) isolating pancreatic stem cells or pancreatic progenitor cells, wherein isolating the pancreatic stem cells or progenitor cells
5 comprises detecting cells in pancreatic tissue that express ZSCAN4; (ii) expanding the isolated pancreatic stem cells or progenitor cells that express ZSCAN4 *in vitro*; and (iii) transplanting the expanded pancreatic stem cells or progenitor cells into the subject. In particular examples, the pancreatic stem cells or progenitor cells are isolated from the subject to be treated.

10 Further provided is an *in vivo* method of expanding a population of pancreatic stem cells or progenitor cells in a subject. In some embodiments, the method includes delivering to the pancreas of the subject a ZSCAN4 protein; a ZSCAN4 nucleic acid sequence; or an agent that increases expression of ZSCAN4 or increases the number of ZSCAN4⁺ cells.

15 Also provided are screening assays to identify agents that stimulate pancreatic stem cells to regenerate exocrine and endocrine cells (including insulin-secreting pancreatic beta cells) by identifying agents that increase expression of ZSCAN4.

A. *Methods of isolating pancreatic stem cells and progenitor cells*

20 Provided herein is a method of isolating pancreatic stem cells or pancreatic progenitor cells, or both, from a sample. In some embodiments, the method includes detecting expression of ZSCAN4 (such as detecting the presence of a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth as SEQ ID NO: 2) in
25 cells of the sample and isolating the cells that express ZSCAN4. In particular examples, the sample comprises human pancreatic tissue.

In some embodiments of the disclosed methods, detecting expression of ZSCAN4 includes detecting expression of a gene that is co-expressed with ZSCAN4.

Described herein is the finding that SSEA3, a known stem cell marker, exhibits a similar expression pattern as ZSCAN4 in pancreatic tissue (see FIG. 11). Thus, in particular examples, the gene that is co-expressed with ZSCAN is SSEA3. Other genes have been identified as co-expressed with ZSCAN4. For example, PCT Publication No. 5 WO 2008/118957 discloses that AF067063, Tcstv1/3, Tho4, Arginase II, BC061212 and Gm428, Eif1a, EG668777 and Pif1 are co-expressed genes. Thus in some embodiments, the gene that is co-expressed with ZSCAN4 is selected from the group consisting of AF067063, Tcstv1/3, Tho4, Arginase II, BC061212 and Gm428, Eif1a, EG668777 and Pif1. In one non-limiting example, the gene that is co-expressed with 10 ZSCAN4 is Tcstv1/3.

The co-expressed gene need not exhibit an identical expression pattern to ZSCAN4 but generally exhibits an expression pattern that is very similar to ZSCAN4 such that the majority of cells (such as at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95%) that are 15 isolated by detecting the ZSCAN4 co-expressed gene also express ZSCAN4.

In some embodiments, the gene that is co-expressed with ZSCAN4 encodes a membrane protein to facilitate antibody-based detection of the protein.

In some embodiments, detecting expression of ZSCAN4 comprises contacting the sample with an antibody specific for a protein encoded by ZSCAN4 or an antibody 20 specific for a protein encoded by a gene co-expressed with ZSCAN4. In particular examples, the antibody is specific for a protein encoded by ZSCAN4. In other examples, the antibody is specific for a protein encoded by SSEA3. In yet other examples, the antibody is specific for a protein encoded by Tcstv1/3. Antibodies specific for proteins encoded by ZSCAN4, SSEA3 and Tcstv1/3 are commercially 25 available and/or can be generating using methods well known to one of skill in the art (see Table 1 for examples of ZSCAN4 antibodies).

Antibody-mediated detection and isolation methods are well known to those of skill in the art. In some cases, the antibody specific for ZSCAN4, or a gene product

encoded by a gene co-expressed with ZSCAN4, is bound to a detectable label, such as a fluorophore. Thus, in particular embodiments, a ZSCAN4-specific antibody conjugated to a fluorophore is contacted with cells of the sample. ZSCAN4⁺ cells will bind the antibody and can be isolated, for example, by fluorescence activated cell sorting (FACS). Similarly, fluorophore-conjugated antibodies specific for gene products of ZSCAN4 co-expressed genes can be contacted with cells of the sample to isolate cells that express the ZSCAN4 co-expressed gene, thereby isolating ZSCAN4⁺ cells. Antibodies can also be conjugated to other detectable markers, such as magnetic beads (to allow for magnetic separation of ZSCAN4⁺ cells).

10 In other embodiments, detecting expression of ZSCAN4 comprises transfecting the cells of the sample with a vector comprising a ZSCAN4 promoter operably linked to a heterologous nucleic acid sequences, such as a reporter gene or a selectable marker. The heterologous nucleic acid sequence can encode any type of molecule that allows for detection and/or selection of cells that express ZSCAN4. In some examples, the
15 heterologous nucleic acid sequence is a reporter gene. The reporter gene can be, for example, a fluorescent protein or enzyme. In particular non-limiting examples, the fluorescent protein is GFP, or a derivative thereof, such as Emerald. Use of a fluorescent marker allows for isolation of cells using, for example, FACS.

In other examples, the heterologous nucleic acid molecule is a selectable
20 marker. In some examples, the selectable marker is an antibiotic resistance gene. Suitable antibiotic resistance genes include, but are not limited to, genes that confer resistance to puromycin, blasticidin, hygromycin, gentamicin, G418 and the like. One of skill in the art can readily choose an appropriate selectable marker for mammalian cells and the corresponding antibiotic to select cells that express ZSCAN4. If the vector
25 includes an antibiotic resistance gene, cells transfected with the vector can be cultured in the presence of the corresponding antibiotic. Cells that express ZSCAN4 will also express the antibiotic resistance gene and survive in the presence of the antibiotic; cells that do not express ZSCAN4 will die, thereby allowing for isolation of ZSCAN4⁺ cells.

JL

In some embodiments, the promoter comprises at least a portion of the human ZSCAN4 promoter. In particular examples, the promoter comprises the human ZSCAN4 promoter. In other embodiments, the ZSCAN4 promoter comprises at least a portion of the mouse Zscan4c promoter. In particular examples, the Zscan4c promoter comprises the nucleic acid sequence set forth as nucleotides 906-4468 of SEQ ID NO: 15.

In some embodiments, the vector for detection of ZSCAN4⁺ cells comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth as SEQ ID NO: 15, and in some examples comprises SEQ ID NO: 15.

In some embodiments disclosed herein, the method further includes detecting expression of a known tissue stem cell marker, such as, but not limited LGR5 or BMI1. Thus, in particular examples, the method further includes detecting expression of LGR5 or BMI1, or both, and isolating cells that also express LGR5 or BMI1, or both.

15

B. Methods of treating a disease or disorder of the pancreas

Also provided herein is a method of treating a subject with a disease or disorder of the pancreas. The disease or disorder of the pancreas can be associated with the endocrine function of the pancreas or the exocrine function of the pancreas. In some cases, the disease or disorder associated with the endocrine function of the pancreas is diabetes.

Transplantation of insulin-producing islet cells, or pancreatic stem/progenitor cells capable of differentiation into such cells, isolated *in vitro* from a donor pancreas has the potential to cure type 1 and some cases of type 2 diabetes (Serup *et al.*, *BMJ* 322:29-32, 2001). However, a lack of sufficient donor cells, and the side effects of immunosuppressive therapy required to successfully transplant allogeneic cells into a subject in need of therapy, have limited the potential of this treatment option. The

methods disclosed herein for isolating pancreatic stem cells and progenitor cells provide a means for overcoming these difficulties.

Provided herein is a method of treating diabetes in a subject. In some embodiments, the method includes (i) isolating pancreatic stem cells or pancreatic progenitor cells, wherein isolating the pancreatic stem cells or progenitor cells includes
5 detecting cells in pancreatic tissue that express ZSCAN4 (such as a ZSCAN4 sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to the sequence set forth as SEQ ID NO: 2); (ii) expanding the isolated pancreatic stem cells or progenitor cells that express
10 ZSCAN4 *in vitro*; and (iii) transplanting the expanded pancreatic stem cells or progenitor cells into the subject. In particular examples, the pancreatic stem cells or progenitor cells are isolated from the subject to be treated. In some embodiments, the method further includes selecting a subject in need of treatment, such as a subject that has been diagnosed with diabetes (including type 1 or type 2 diabetes).

15 The pancreatic tissue can be obtained from the subject to be treated or from a donor subject using standard methods, such as by surgery or biopsy. Biopsies of the pancreas can be performed according to any standard method, such as fine needle aspiration (FNA), core biopsy or laparoscopy (Paulsen *et al.*, *Interventional Radiology* 187:769-772, 2006; Freeny *et al.*, *West J Med* 132:283-287, 1980). In particular
20 examples, pancreatic tissue is obtained using a 19-gauge TRU-CUT™ biopsy needle under visual guidance of endoscopic ultrasonography.

In some embodiments, the method further includes differentiating the pancreatic stem cells or progenitor cells into pancreatic β cells before transplanting the cells into the subject. Methods of culturing pancreatic cells and differentiating pancreatic stem
25 cells or progenitor cells (such as into β cells) *in vitro* has been described (see, for example, Ramiya *et al.*, *Nat Med* 6:278-282, 2000; Bonner-Weir *et al.*, *Proc Natl Acad Sci USA* 97(14):7999-8004, 2000; U.S. Patent Application Publication Nos. 2005/0069529 and 2008/0274090).

Transplantation of the pancreatic cells (stem cell, progenitor cells or differentiated cells) into the subject in need of treatment can be accomplished using any suitable method known in the art. In some embodiments, the pancreatic cells are delivered by direct injection into the pancreas. As one example, the pancreatic cells can be transplanted by puncturing the kidney capsule with a hypodermic needle, threading a thin capillary tube through the puncture site into the kidney and injecting the cells into the cortex region of the pancreas (such as is described in U.S. Patent Application Publication No. 2008/0274090). In another example, pancreatic cells are transplanted by placing a catheter through the upper abdomen and into the portal vein of the liver. Pancreatic cells are then slowly infused into the liver.

In some embodiments, the expanded pancreatic stem cells, progenitor cells or β cells are administered alone, in the presence of a pharmaceutically acceptable carrier (such as encapsulated in a suitable polymer) or in the presence of other therapeutic agents.

In one example, the pancreatic cells are encapsulated into a semipermeable polymer membrane and the polymer membrane transplanted into the diabetic subject (see U.S. Patent No. 5,573,528 for description of encapsulation of compounds and cells).

The semipermeable polymer membrane can be synthetic or natural. Examples of polymer that can be used include polyethersulfone (PES), polyacrylonitrile-co-vinyl chloride (P[AN/VC], poly(lactic acid), poly(lactic-co-glycolic acid), methylcellulose, hyaluronic acid, collagen, and the like. Delivery of encapsulated pancreatic cells within a polymer membrane can avoid host rejection and immune response to cells, and problems associated with rejection and inflammation. In addition, cells contained within the polymer membrane are shielded by the wall of the polymer (*i.e.*, the walls of the individual fibers, fibrils, films, sprays, droplets, particles, etc.) from immune surveillance while still maintaining cell viability and allowing transport of molecules, nutrients and metabolic products through the polymer walls. The grafting of polymer-

encapsulated cells has been developed by Aebischer *et al.* (*Transplant*, 111:269-275, 1991) and has been successfully used with both non-human primates and humans (Aebischer *et al.*, 1994, *Transplant*, 58:1275-1277; U.S. Patent No. 6,110,902).

In one example, the expanded pancreatic cells are encapsulated by first
5 embedding them into a matrix of either collagen, agarose or PVA (polyvinylalcohol). Subsequently, the embedded cells are injected into hollow fibers made of polypropylene of a 60:40 copolymer of polyacrylnitrile:polyvinylchloride. The fibers are cut into pieces and end-sealed for implantation.

10 C. *Methods of expanding pancreatic stem/progenitor cells in vivo*

Further provided herein is an *in vivo* method of expanding a population of pancreatic stem cells or progenitor cells in a subject. In some embodiments, the method includes delivering to the pancreas of the subject a ZSCAN4 protein; a ZSCAN4
nucleic acid sequence; or an agent that increases expression of ZSCAN4 or increases
15 the number of ZSCAN4⁺ cells. In some embodiments, the method further includes selecting a subject in need of expansion of pancreatic stem cells or progenitor cells. For example, the subject can be a subject with diabetes.

In some embodiments, the ZSCAN4 protein or nucleic acid sequences is a human ZSCAN4 protein or nucleic acid sequence. In other embodiments, the ZSCAN4
20 protein or nucleic acid sequence is a murine Zscan4 sequence.

In some embodiments, the amino acid sequence of the ZSCAN4 protein is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the amino acid sequence of SEQ ID NO: 2. In some examples, the ZSCAN4 protein comprises the amino acid sequence of SEQ ID NO: 2.
25 In particular non-limiting examples, the ZSCAN4 protein consists of the amino acid sequence of SEQ ID NO: 2. In other examples, the ZSCAN4 protein comprises a functional fragment of SEQ ID NO: 2 or a conservative variant of SEQ ID NO: 2.

In some embodiments, the ZSCAN4 nucleic acid sequence is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the nucleic acid sequence of SEQ ID NO: 1. In some examples, the ZSCAN4 nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO: 1.

5 In particular non-limiting examples, the ZSCAN4 nucleic acid sequence consists of the nucleotide sequence of SEQ ID NO: 1. In other examples, the ZSCAN4 nucleic acid sequence encodes a functional fragment or a conservative variant of the ZSCAN4 protein of SEQ ID NO: 2.

In some embodiments, delivery of the ZSCAN4 nucleic acid sequence includes
10 administration of a vector that comprises the ZSCAN4 nucleic acid sequence. Methods of generating and using ZSCAN4-expressing vectors are described in other sections of the application.

In some embodiments, delivery of the ZSCAN4 protein or the ZSCAN4 nucleic acid sequence (such as a vector comprising a ZSCAN4 nucleic acid sequence) includes
15 administration of a ZSCAN4 protein or nucleic acid encapsulated by a nanoparticle. Methods of delivering proteins and nucleic acid molecules using nanoparticles are well known in the art and are described below in section V.D.

The inventors have previously demonstrated that retinoids can transiently increase Zscan4⁺ cells in mouse ES cell culture (PCT/US2010/047644, filed September
20 2, 2010). Thus, in some embodiments, the agent that increases expression of ZSCAN4 is a retinoid. Exemplary retinoids include, but are not limited to atRA, 9-cis RA, 13-cis RA and vitamin A.

Delivery of the ZSCAN4 protein, ZSCAN4 nucleic acid, or agent that increases expression of ZSCAN4 (or increases the number of ZSCAN4⁺ cells) can be
25 accomplished using any suitable method known in the art and will vary depending upon the molecule or composition to be delivered. In some embodiments, the ZSCAN4 protein, ZSCAN4 nucleic acid, or agent that increases expression of ZSCAN4 or increases the number of ZSCAN4⁺ cells is delivered to the pancreas of the subject by

injection. In other embodiments, the agent is injected into the local or systemic blood circulation to allow for delivery of the agent to the pancreas. In yet other embodiments, the agent is administered orally.

5 D. *Screening assays*

Further provided herein are screening assays to identify agents that stimulate pancreatic stem cells to regenerate exocrine and endocrine cells (including insulin-secreting pancreatic beta cells) by identifying agents that increase expression of ZSCAN4 or increase the number of ZSCAN4⁺ cells in a given population of cells (such
10 as cells in the pancreas). In some embodiments, the method includes contacting a cell culture with a candidate agent and detecting expression of ZSCAN4. An increase in expression of ZSCAN4 following addition of the agent to the cell culture relative to a control, indicates the agent is capable of stimulating pancreatic stem cells to regenerate exocrine and endocrine cells. The control can be, for example, the level of ZSCAN4
15 expression prior to addition of the agent, expression of ZSCAN4 in a control cell culture, or a reference value, such as a value that is representative of ZSCAN4 expression in a similar cell culture in the absence of an exogenous agent.

In some embodiments, the cell culture comprises pancreatic cells, such as primary pancreatic cells, or cells of a pancreatic cell line. In other embodiments, the
20 cell culture comprises pluripotent stem cells, such as embryonic stem cells.

In some embodiments, the assay includes detecting expression of ZSCAN4 mRNA, such as by PCR. In other embodiments, the assay includes detecting expression of ZSCAN4 protein, such as by ELISA. In yet other embodiments, the assay includes detecting expression of a reporter (such as GFP) under the control of a ZSCAN4
25 promoter.

Agents that are identified using the disclosed screening assays can be used, for example, to administer to a subject in order to expand pancreatic stem/progenitor cells *in vivo*.

IV. *Zscan4 Promoter Sequences and Expression Vectors*

Expression vectors comprising a ZSCAN4 promoter and a reporter gene have been previously described (see PCT Publication No. WO 2008/118957). An expression
5 vector comprising a ZSCAN4 promoter sequence operably linked to a nucleic acid sequence encoding a heterologous polypeptide (such as a reporter gene or selectable marker) can be used to identify cells that express ZSCAN4. Methods of detecting expression of the reporter gene, and thus the ZSCAN4+ cells, vary depending upon the type of reporter gene, but are well known in the art. For example, when a fluorescent
10 reporter is used, detection of expression can be achieved by FACS or fluorescence microscopy. In other examples, when a selectable marker is used, such as an antibiotic resistance gene, the cells are incubated in the presence of an appropriate selection agent (such as antibiotic), which will kill all cells that do not express ZSCAN4.

In some examples a heterologous nucleic acid sequence (such as a reporter
15 molecule) is expressed under the control of a ZSCAN4 promoter (for example in a vector). In some embodiments, the ZSCAN4 promoter is the mouse *Zscan4c* promoter. For example, the *Zscan4c* promoter can include the nucleic acid sequence set forth as nucleotides 906-4468 of SEQ ID NO: 15. In some examples, the *Zscan4c* promoter comprises *Zscan4c* exon and/or intron sequence. Other expression control sequences,
20 including appropriate enhancers, transcription terminators, a start codon (*i.e.*, ATG) in front of a protein-encoding gene, splicing signals for introns, and stop codons can be included with the ZSCAN4 promoter in an expression vector. Generally the promoter includes at least a minimal sequence sufficient to direct transcription of a heterologous nucleic acid sequence. In several examples, the heterologous nucleic acid sequence
25 encodes a reporter molecule or a selectable marker (such as an antibiotic resistance gene).

The heterologous protein encoded by the heterologous nucleic acid sequence is typically a reporter molecule or selectable maker, such as a marker, an enzyme, a

fluorescent protein, a polypeptide that confers antibiotic resistance to the cell, or an antigen that can be identified using conventional molecular biology procedures.

Reporter molecules can be used to identify a cell, or a population of cells, of interest, such as ZSCAN4⁺ pancreatic cells. In one embodiment, the heterologous protein is a

5 fluorescent marker (such as a green fluorescent protein, or a variant thereof, *e.g.* Emerald (Invitrogen, Carlsbad, CA)) an antigenic marker (such as human growth hormone, human insulin, human HLA antigens); a cell-surface marker (such as CD4, or any cell surface receptor); or an enzymatic marker (such as lacZ, alkaline phosphatase). Expression of the reporter gene indicates the cell expresses Zscan4. Methods of
10 detecting expression of the reporter gene vary depending upon the type of reporter gene and are well known in the art. For example, when a fluorescent reporter is used, detection of expression can be achieved by FACS or fluorescence microscopy.

In another embodiment, the heterologous protein confers antibiotic resistance, such as resistance to puromycin. Thus, the cells are incubated in the presence of the
15 appropriate antibiotic (such as puromycin) to select for cells that express ZSCAN4.

Expression vectors typically contain an origin of replication as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use are well known in the art, including viral vectors and plasmid vectors (including those described in Section V below). In one example, an enhancer is located upstream
20 of the ZSCAN4 promoter, but enhancer elements can generally be located anywhere on the vector and still have an enhancing effect. However, the amount of increased activity will generally diminish with distance. Additionally, two or more copies of an enhancer sequence can be operably linked one after the other to produce an even greater increase in promoter activity.

25 Expression vectors including a ZSCAN4 promoter can be used to transform host cells, such as, but not limited to pancreatic cells. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art, and can be used to transfect any cell of interest.

A “transfected cell” is a host cell into which (or into an ancestor of which) has been introduced a nucleic acid molecule (*e.g.*, DNA molecule), such as a DNA molecule including a ZSCAN4 promoter element. Transfection of a host cell with a recombinant nucleic acid molecule may be carried out by conventional techniques as
5 are well known to those skilled in the art. As used herein, transfection includes liposomal-mediated transfection, electroporation, injection or any other suitable technique for introducing a nucleic acid molecule into a cell.

V. *Zscan4 Polynucleotide and Polypeptide Sequences*

10 ZSCAN4 nucleic acid and amino acid sequences have been previously described in the art (see, for example, WO 2008/118957, the disclosure of which is herein incorporated by reference; Falco *et al.*, *Dev. Biol.* 307(2):539-550, 2007; and Carter *et al.*, *Gene Expr. Patterns.* 8(3):181-198, 2008). As used herein, the term “ZSCAN4” includes human ZSCAN4, any one of a group of mouse genes exhibiting 2-cell
15 embryonic stage- or ES cell-specific expression (including Zscan4a, Zscan4b, Zscan4c, Zscan4d, Zscan4e and Zscan4f), or any other species ortholog of ZSCAN4.

A. *ZSCAN4 amino acid sequences*

Exemplary ZSCAN4 amino acid sequences are set forth in the Sequence Listing
20 as SEQ ID NO: 2 (human ZSCAN4), SEQ ID NO: 4 (Zscan4a), SEQ ID NO: 6 (Zscan4b), SEQ ID NO: 8 (Zscan4c), SEQ ID NO: 10 (Zscan4d), SEQ ID NO: 12 (Zscan4e) and SEQ ID NO: 14 (Zscan4f). One skilled in the art will appreciate that sequences having at least 80%, at least 90%, at least 95%, or at least 98% sequence
25 identity to these sequences and retain ZSCAN4 activity (such as the ability to enhance genome stability and increase telomere length in a ES cell) can be used in the methods provided herein.

ZSCAN4 amino acid sequences from other species are publically available, including dog ZSCAN4 (GenBank Accession Nos. XP_541370 and XP_853650); cow

ZSCAN4 (GenBank Accession No. XP_001789302); and horse ZSCAN4 (GenBank Accession No. XP_001493994). Each of the above-listed GenBank Accession numbers is herein incorporated by references as it appears in the GenBank database on January 14, 2011.

5 Specific, non-limiting examples of ZSCAN4 polypeptides that can be expressed in cells (such as pancreatic cells), or delivered *in vivo* (such as to the pancreas) according to the methods provided herein include polypeptides having an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% homologous to the amino acid sequence set forth in
10 SEQ ID NO: 2, 4, 6, 8, 10, 12 or 14. In a further embodiment, a ZSCAN4 polypeptide is a conservative variant of SEQ ID NO: 2, 4, 6, 8, 10, 12 or 14, such that it includes no more than fifty conservative amino acid substitutions, such as no more than two, no more than five, no more than ten, no more than twenty, or no more than fifty conservative amino acid substitutions in SEQ ID NO: 2, 4, 6, 8, 10, 12 or 14. In another
15 embodiment, a ZSCAN4 polypeptide has an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO: 2, 4, 6, 8, 10, 12 or 14. In another embodiment, a ZSCAN4 polypeptide has an amino acid sequence consisting of the amino acid sequence set forth in SEQ ID NO: 2, 4, 6, 8, 10, 12 or 14.

 Fragments and variants of a ZSCAN4 polypeptide can readily be prepared by
20 one of skill in the art using molecular techniques. In one embodiment, a fragment of a ZSCAN4 polypeptide includes at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450 or at least 500 consecutive amino acids of the ZSCAN4 polypeptide. In a further embodiment, a fragment of ZSCAN4 is a fragment that confers a function of ZSCAN4 when transferred into a cell of interest.

25 Minor modifications of the ZSCAN4 polypeptide primary amino acid sequences may result in peptides which have substantially equivalent activity as compared to the unmodified counterpart polypeptide described herein. Such modifications may be

deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein.

One of skill in the art can readily produce fusion proteins including a ZSCAN4 polypeptide and a second polypeptide of interest. Optionally, a linker can be included
5 between the ZSCAN4 polypeptide and the second polypeptide of interest. Fusion proteins include, but are not limited to, a polypeptide including a ZSCAN4 polypeptide and a marker protein. In one embodiment, the marker protein can be used to identify or purify a ZSCAN4 polypeptide. Exemplary fusion proteins include, but are not limited to, green fluorescent protein, six histidine residues, or myc and a ZSCAN4 polypeptide.

10 One skilled in the art will appreciate that such variants, fragments, and fusions of Zscan4 useful for the disclosed methods are those that retain ZSCAN4 activity.

B. ZSCAN4 nucleic acid sequences

Nucleic acid molecules encoding a Zscan4 polypeptide are termed Zscan4
15 polynucleotides or nucleic acid molecules. These polynucleotides include DNA, cDNA and RNA sequences which encode a ZSCAN4 protein. It is understood that all polynucleotides encoding a ZSCAN4 polypeptide are also included herein, as long as they encode a polypeptide with a recognized ZSCAN4 activity, such as the ability to modulate genome stability or telomere length in an ES cell. The polynucleotides
20 include sequences that are degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included as long as the amino acid sequence of the ZSCAN4 polypeptide encoded by the nucleotide sequence is functionally unchanged. A ZSCAN4 polynucleotide encodes a ZSCAN4 polypeptide, as disclosed
25 herein. Exemplary polynucleotide sequences encoding ZSCAN4 that can be expressed in cells, or delivered to cells or tissues, using the methods provided herein are set forth in the Sequence Listing as SEQ ID NO: 1 (human ZSCAN4), SEQ ID NO: 3 (Zscan4a),

SEQ ID NO: 5 (Zscan4b), SEQ ID NO: 7 (Zscan4c), SEQ ID NO: 9 (Zscan4d), SEQ ID NO: 11 (Zscan4e), and SEQ ID NO: 13 (Zscan4f).

ZSCAN4 nucleic acid sequences from other species are publically available, including dog ZSCAN4 (GenBank Accession Nos. XM_541370 and XM_848557); cow
5 ZSCAN4 (GenBank Accession No. XM_001789250); and horse ZSCAN4 (GenBank Accession No. XM_001493944). Each of the above-listed GenBank Accession numbers is herein incorporated by references as it appears in the GenBank database on January 14, 2011.

In some embodiments, the ZSCAN4 polynucleotide sequence expressed in or
10 delivered to a cell (such as a pancreatic cell) according to the methods provided herein is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 1, 3, 5, 7, 9, 11 or 13. In some embodiments, the ZSCAN4 polynucleotide sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11 or 13. In some embodiments, the
15 Zscan4 polynucleotide sequence consists of the nucleic acid sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11 or 13.

Fragments and variants of ZSCAN4 polynucleotides can readily be prepared by one of skill in the art using molecular techniques. In one embodiment, a fragment of a ZSCAN4 polynucleotide includes at least 250, at least 500, at least 750, at least 1000, at
20 least 1500, or at least 2000 consecutive nucleic acids of the ZSCAN4 polynucleotide. In a further embodiment, a fragment of ZSCAN4 is a fragment that confers a function of ZSCAN4 when expressed in a cell of interest.

Minor modifications of the ZSCAN4 polynucleotide sequences may result in expression of peptides which have substantially equivalent activity as compared to the
25 unmodified counterpart polynucleotides described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polynucleotides produced by these modifications are included herein.

C. *Vectors encoding ZSCAN4*

ZSCAN4 polynucleotides include recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (*e.g.*, a cDNA)
5 independent of other sequences. The nucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. The term includes single- and double-stranded forms of DNA.

With the provision of several ZSCAN4 nucleic acid and protein sequences described above, the expression of any ZSCAN4 protein (*e.g.*, a heterologous ZSCAN4
10 protein) in cell (such as a pancreatic cell) using standard laboratory techniques is enabled. In some examples, the ZSCAN4 nucleic acid sequence is under the control of a promoter. In some examples, a vector system is used to express ZSCAN4, such as plasmids, bacteriophages, cosmids, animal viruses and yeast artificial chromosomes (YACs). These vectors may then be introduced into pancreatic cells.

15 A ZSCAN4 coding sequence may be operably linked to a heterologous promoter, to direct transcription of the ZSCAN4 coding nucleic acid sequence. A promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements which can be located as
20 much as several thousand base pairs from the start site of transcription. In one example, the promoter is a constitutive promoter, such as the CAG-promoter (Niwa *et al.*, *Gene* 108(2):193-9, 1991), or the phosphoglycerate kinase (PGK)-promoter. In another example, the promoter is an inducible promoter such as a tetracycline-inducible promoter (Masui *et al.*, *Nucleic Acids Res.* 33:e43, 2005). Other exemplary promoters
25 that can be used to drive ZSCAN4 expression include but are not limited to: *lac* system, the *trp* system, the *tac* system, the *trc* system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus,

baculovirus and simian virus, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, and the promoter of the yeast alpha-mating factors. In some examples, a native ZSCAN4 promoter is used.

5 A vector system can be used to express ZSCAN4. Exemplary vectors that can be used to express Zscan4 in cells include but are not limited to plasmids and viral vectors. In one example, vectors containing the promoter and enhancer regions of the SV40 or long terminal repeat (LTR) of the Rous Sarcoma virus and polyadenylation and splicing signal from SV40 (Mulligan and Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072-6; Gorman *et al.*, 1982, *Proc. Natl. Acad. Sci. USA* 78:6777-81) are used. In one example, 10 the vector is a viral vector, such as an adenoviral vector, an adeno-associated virus (AAV), such as described in U.S. Patent No. 4,797,368 (Carter *et al.*) and in McLaughlin *et al.* (*J. Virol.* 62:1963-73, 1988) and AAV type 4 (Chiorini *et al. J. Virol.* 71:6823-33, 1997) and AAV type 5 (Chiorini *et al. J. Virol.* 73:1309-19, 1999), or retroviral vector (such as the Moloney murine leukemia virus, spleen necrosis virus, and 15 vectors derived from retroviruses such as Rous sarcoma virus, Harvey sarcoma virus, avian leukosis virus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus). Other viral transfection systems may also be utilized, including vaccinia virus (Moss *et al.*, 1987, *Annu. Rev. Immunol.* 5:305-24), bovine papilloma virus (Rasmussen *et al.*, 1987, *Methods Enzymol.* 139:642-54) or members of 20 the herpes virus group such as Epstein-Barr virus (Margolske *et al.*, 1988, *Mol. Cell. Biol.* 8:2837-47). In addition, vectors may contain antibiotic selectable markers (such as neomycin, hygromycin or mycophenolic acid) to permit selection of transfected cells that exhibit stable, long-term expression of the vectors (and therefore the ZSCAN4 nucleic acid).

25

D. Nanoparticles for delivery of ZSCAN4 proteins and nucleic acids

Nanoparticles are submicron (less than about 1000 nm) sized drug delivery vehicles that can carry encapsulated drugs such as synthetic small molecules, proteins,

peptides, cells and nucleic acid based biotherapeutics for either rapid or controlled release. A variety of molecules (*e.g.*, proteins, peptides and nucleic acid molecules) can be efficiently encapsulated in nanoparticles using processes well known in the art.

The nanoparticles for use with the methods described herein can be any type of
5 biocompatible nanoparticle, such as biodegradable nanoparticles, such as polymeric nanoparticles, including, but not limited to polyamide, polycarbonate, polyalkene, polyvinyl ethers, and cellulose ether nanoparticles. In some embodiments, the nanoparticles are made of biocompatible and biodegradable materials. In some
10 poly(lactic acid) or poly(glycolic acid), or both poly(lactic acid) and poly(glycolic acid). In particular embodiments, the nanoparticles are poly(D,L-lactic-*co*-glycolic acid) (PLGA) nanoparticles.

PLGA is a FDA-approved biomaterial that has been used as resorbable sutures and biodegradable implants. PLGA nanoparticles have also been used in drug delivery
15 systems for a variety of drugs via numerous routes of administration including, but not limited to, subcutaneous, intravenous, ocular, oral and intramuscular. PLGA degrades into its monomer constituents, lactic and glycolic acid, which are natural byproducts of metabolism, making the material highly biocompatible. In addition, PLGA is commercially available as a clinical-grade material for synthesis of nanoparticles.

20 Other biodegradable polymeric materials are contemplated for use with the compositions and methods described herein, such as poly(lactic acid) (PLA) and polyglycolide (PGA). Additional useful nanoparticles include biodegradable poly(alkylcyanoacrylate) nanoparticles (Vauthier *et al.*, *Adv. Drug Del. Rev.* 55: 519-48, 2003).

25 Among the biodegradable polymers currently being used for human applications, PLA, PGA, and PLGA are known to be generally safe because they undergo *in vivo* hydrolysis to harmless lactic acid and glycolic acid. These polymers have been used in making sutures when post-surgical removal is not required, and in

formulating encapsulated leuprolide acetate, which has been approved by the FDA for human use (Langer and Mose, *Science* 249:1527, 1990); Gilding and Reed, *Polymer* 20:1459, 1979; Morris, *et al.*, *Vaccine* 12:5, 1994). The degradation rates of these polymers vary with the glycolide/lactide ratio and molecular weight thereof. Therefore, the release of the encapsulated molecule (such as a protein or peptide) can be sustained over several months by adjusting the molecular weight and glycolide/lactide ratio of the polymer, as well as the particle size and coating thickness of the capsule formulation (Holland, *et al.*, *J. Control. Rel.* 4:155, 1986).

In some embodiments, the nanoparticles for use with the compositions and methods described herein range in size from about 50 nm to about 1000 nm in diameter. In some cases, the nanoparticles are less than about 600 nm. In some embodiments, the nanoparticles are about 100 to about 600 nm in diameter. In some embodiments, the nanoparticles are about 200 to about 500 nm in diameter. In some embodiments, the nanoparticles are about 300 to about 450 nm in diameter. One skilled in the art would readily recognize that the size of the nanoparticle may vary depending upon the method of preparation, clinical application, and imaging substance used.

Various types of biodegradable and biocompatible nanoparticles, methods of making such nanoparticles, including PLGA nanoparticles, and methods of encapsulating a variety of compounds, including proteins and nucleic acids, has been well described in the art (see, for example, U.S. Publication No. 2007/0148074; U.S. Publication No. 20070092575; U.S. Patent Publication No. 2006/0246139; U.S. Patent No. 5,753,234; U.S. Patent No. 7,081,489; and PCT Publication No. WO/2006/052285).

The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the disclosure to the particular features or embodiments described.

EXAMPLES

Example 1: Materials and Methods

This example describes the experimental procedures used for the studies described in Example 2.

5

Subjects

Surgically resected pancreatic tissues and pancreatic biopsy samples were used for immunohistochemical analyses. Normal pancreatic tissues that were resected for the treatment of biliary carcinoma were used (n=3). Tissues resected for the treatment of chronic alcoholic pancreatitis (n=3) were also used. Pancreas biopsy samples from 18 patients with autoimmune pancreatitis were reported previously (Ko *et al.*, *Gastroenterology* 138:1988-1996, 2010). All pancreatic biopsies were performed to exclude malignancy and written informed consent was obtained from each patient before the procedure. Under visual guidance of endoscopic ultrasonography (GF-UCT240, Olympus), pancreatic tissues were obtained from the body of the pancreas using a 19-gauge TRU-CUT™ biopsy needle (Wilson-Cook Inc.). Patients met the 2006 revised Japanese clinical diagnostic criteria for autoimmune pancreatitis: diffuse swelling of the pancreas, irregular narrowing of the main pancreatic duct, and a positive test for autoantibodies or a high IgG (≥ 1800 mg/dl)/ IgG4 concentration (≥ 135 mg/dl). Among the 18 patients with autoimmune pancreatitis (Mizuno *et al.*, *J Gastroenterol* 44:742-750, 2009), 3 patients were subjected to pancreatic biopsy to exclude malignancy at three different times: at the time of diagnosis, 3 months after the initiation of corticosteroid treatment, and 1 year after the start of treatment. A standard protocol for oral corticosteroids was used accordingly: prednisolone at 30 mg/day for a week as an initial dose, 20 mg/day for a second week, 10 mg/day for 4 additional weeks, and 5 mg/day as a maintenance dose all through the observation period (Ko *et al.*, *Gastroenterology* 138:1988-1996, 2010).

Immunohistochemistry and Immunofluorescence

Both human and mouse pancreases were fixed in 10% formalin and embedded in paraffin. Embedded tissues were thin-sliced with a Leica microtome (Leica
 5 Microsystems GmbH, Wetzlar, Germany) at 5 μ m. Sections were deparaffinized, permeabilized, and used for immunohistochemical analyses (Ko *et al.*, *Gastroenterology* 138:1988-1996, 2010). Antibodies used in this study are summarized in Table 1.

10 **Table 1: Antibodies Used For Immunohistochemical Analysis**

Antibodies	Species	Manufacturer	Product ID	Working Dilution
Anti-aquaporin1	Rabbit	ALPHA DIAGNOSTICS	AQP11-A	IHC 1 : 500
				IF 1 : 500
Anti-amylase	Mouse	Abcam	ab54765	IHC 1 : 300
				IF 1 : 100
Anti-BMI1	Mouse	MILLIPORE	05-637	IHC 1 : 200
				IF 1 : 100
Anti-CFTR (#570)	Mouse	gift from Dr.Riordan (University of North Carolina)		IHC 1 : 600
				IF 1 : 300
Anti-CD163	Mouse	Leica	NCL-CD163	IHC 1 : 300
				IF 1 : 100
Anti-ghrelin	Rabbit	Abcam	ab64325	IHC 1 : 6000
				IF 1 : 1000
Anti-glucagon	Rabbit	Abcam	ab18461	IHC 1 : 5000
				IF 1 : 1000
Anti-insulin	Guinea pig	Abcam	ab7842	IHC 1 : 500
				IF 1 : 2000
Anti-insulin	Mouse	Abcam	ab7760	IHC 1 : 3000
				IF 1 : 2000

	Antibodies	Species	Manufacturer	Product ID	Working Dilution	
5	Anti-LGR5	Rabbit	Abcam	ab75732	IHC	1 : 300
					IF	1 : 100
10	Anti-Somatostatin Rat		Abcam	ab30788	IHC	1 : 1000
					IF	1 : 500
10	Anti-mZscan4	Rabbit	NIA/NIH*	H00201516-B01P	IHC	1 : 2000
	Anti-hZSCAN4	Mouse	Abnova		IHC	1 : 200
					IF	1 : 100

IHC, Immunohistochemistry; IF, Immunofluorescence

* Zalzman *et al.*, Nature 464:858-863, 2010

15 Antibodies were diluted according to the manufacturer's recommendation.

Immunoreactions were intensified using Histofine Simple Stain MAX-PO (Nichirei Biosciences, Inc, Tokyo, Japan). Immunolabelling was visualized using 3, 3'-diaminobenzidinetetrahydrochloride (DAB) as substrate for horseradish peroxidase. Sections were counterstained with Mayer's hematoxylin. For immunofluorescence, 20 ALEXA FLUOR™ 488 (green) or ALEXA FLUOR™ 596 (red) labeled secondary antibodies were used for double staining. Immunolabelling was photographed with Olympus fluorescence microscopy (AX80; Olympus, Tokyo, Japan). Cell nuclei were counterstained with Hoechst 33342.

25 **Materials**

All the reagents in molecular biology grade were obtained from Sigma-Aldrich (St. Louis, MO) otherwise stated.

Example 2: Progenitor/stem cells marked with ZSCAN4 in adult human pancreas

30 This example describes the finding that a small number of ZSCAN4-positive cells are present among cells located in the islets of Langerhans, acini, and ducts of the adult pancreas. The results described in this example indicate that ZSCAN4 expression is a marker of rare stem/progenitor cells in the adult human pancreas.

Expression and localization of ZSCAN4 in adult human pancreas

Immunostaining with a specific antibody raised against human ZSCAN4 revealed that the majority of human pancreatic tissues were negative for ZSCAN4 staining, but a small number of cells showed strong nuclear staining for ZSCAN4 (FIG. 1A). More specifically, in the endocrine part of human pancreas, the majority of the islet of Langerhans did not show any ZSCAN4 staining, whereas some (<1%) of the islet of Langerhans showed ZSCAN4 staining; a few cells with strong nuclear staining and some of the remaining cells showed weak cytoplasmic staining (FIG. 1B). In the exocrine part of human pancreas, the majority of acinar cells did not show any ZSCAN4 staining, whereas some (<1%) acinar cells showed weak ZSCAN4 staining with occasional strong nuclear staining in a few cells (FIG. 1C). Furthermore, a small number of ZSCAN4-positive (ZSCAN4⁺) cells were also found in pancreatic ducts (FIG. 1D). ZSCAN4 was also expressed in oval-shaped cells located in the region between pancreatic acini (FIG. 1E). From their location and cell morphology, these oval-shaped cells (tentatively called “pancreatic oval cells”) can be identified as one form of pancreatic stellate cells (Bachem *et al.*, *Gastroenterology* 115:421-432, 1998; Apte *et al.*, *Gut* 43:128-133, 1998).

As validation for the human ZSCAN4 antibody, it was observed that both antibodies against human ZSCAN4 and mouse ZSCAN4 marked almost identical cells on either human (FIGS. 1F-1H and FIG. 1A-C) or mouse (FIGS. 6D-6L) pancreas sections. Because mouse ZSCAN4 is a specific marker for pluripotent ES cells (Falco *et al.*, *Dev Biol* 307:539-550, 2007; Carter *et al.*, *Gene Expr Patterns* 8:181-198, 2008) and is involved in genome stability in mouse ES cells (Zalzman *et al.*, *Nature* 464:858-863, 2010), these immunohistological data indicate that ZSCAN4⁺ cells are a good candidate for pancreatic tissue stem cells, which had been previously postulated, but not yet discovered (Aguayo-Mazzucato *et al.*, *Nat Rev Endocrinol* 6:139-148, 2010).

Expression and localization of LGR5 and BMI1 in human pancreas

To further investigate ZSCAN4⁺ cells in the pancreas, two other proteins were selected that are well-established as tissue stem cell markers in mice: polycomb ring finger oncogene (BMI1) and leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5). BMI1 is necessary for efficient self-renewing cell divisions of adult mouse hematopoietic stem cells (Raaphorst, *Trends Immunol* 24:522-524, 2003). A single BMI1-expressing cell has been shown to form all the cell lineages in the intestinal epithelium (Ootani *et al.*, *Nat Med* 15:701-706, 2009) and BMI1-lineage tracing has identified self-renewing pancreatic acinar cells capable of pancreatic organ homeostasis (Sangiorgi and Capecchi, *Proc Natl Acad Sci USA* 106:7101-7106, 2009). LGR5 is expressed in several organs (Barker and Clevers, *Gastroenterology* 138:1681-1696, 2010) and genetic marking of LGR5⁺ cells has identified this membrane protein as a marker for intestinal and skin tissue stem cells in mice (Barker *et al.*, *Nature* 449:1003-1007, 2007; Snippert *et al.*, *Science* 327:1385-1389, 2010).

Immunohistochemical analyses showed that both BMI1 and LGR5 were detected in a small number of cells inside of the islets of Langerhans (FIG. 2A and FIG. 2D, respectively), duct cells (FIG. 2B and FIG. 2E, respectively), pancreatic acinar cells (FIG. 2C and FIG. 2D, respectively), and pancreatic oval cells located between adjacent acini (asterisks in FIG. 2C and FIG. 2F, respectively). Taken together, the localization of ZSCAN4⁺, BMI1⁺ and LGR5⁺ cells were similar to each other; however, in general, BMI1⁺ and LGR5⁺ cells were more abundant than ZSCAN4⁺ cells.

Presence of cells co-stained with ZSCAN4, BMI1, and LGR5 in human pancreas

To examine if ZSCAN4, BMI1, and LGR5 are expressed in the same cells, double staining by immunofluorescence was performed in the same series of human paraffin sections. Cells expressing BMI1 and cells expressing LGR5 were mostly overlapped in human pancreatic sections, although slightly more LGR5⁺ cells were noted than BMI1⁺ cells (FIGS. 2G-2J). In contrast, ZSCAN4 expression was found

only in a subset (5-10%) of LGR5⁺ cells (FIG. 2K-2N). These results are in good agreement with the expression pattern of ZSCAN4 protein in mouse ES cells, where Zscan4 is transiently expressed and only about 5% of ES cells are positive for Zscan4 at a given time (Zalzman *et al.*, *Nature* 464:858-863, 2010). The term

5 “BMI1⁺LGR5⁺ZSCAN4^{+&-}” is used to indicate the cells that are marked with the co-expression of BMI1 and LGR5 and have capacity to express ZSCAN4 intermittently.

BMI1⁺LGR5⁺ZSCAN4^{+&-} cells express neither pancreatic endocrine hormones nor exocrine enzyme amylase

10 To examine if BMI1⁺LGR5⁺ZSCAN4^{+&-} cells have a phenotype of differentiated cells, fluorescence-based co-staining was carried out with the combination of an antibody against LGR5 and an antibody against one of the endocrine hormones or exocrine enzyme amylase.

In pancreatic islets, LGR5⁺ cells were all negative for insulin (FIGS. 3A-3D and
15 FIGS. 8A-8C), glucagon (FIGS. 7A-7D and FIGS. 8D-8F), somatostatin (FIGS. 7E-7H and FIGS. 8G-8I), and ghrelin (FIGS. 7I-7L and FIGS. 8J-8L). Lack of expression of these endocrine hormones indicates that these BMI1⁺LGR5⁺ZSCAN4^{+&-} cells do not belong to known differentiated cells located in the islet of Langerhans, suggesting the presence of a novel cell type, possibly tissue stem/progenitor cells. A small number of
20 endocrine hormones-expressing cells were also observed in pancreatic ducts (FIGS. 8C, 8F, 8I, and 8L) and pancreatic acini (FIGS. 8B, 8E, 8H, and 8K), which is consistent with previous reports (Bertelli and Bendayan, *Am J Physiol* 273:C1641-1649, 1997) (FIGS. 9D-9F).

In pancreatic acini, BMI1⁺LGR5⁺ZSCAN4^{+&-} cells were negative for digestive
25 enzyme amylase – a specific marker for pancreatic exocrine cells (FIGS. 3E-3H), suggesting the presence of a novel cell type, possibly tissue stem/progenitor cells, in pancreatic acini.

Expression of AQP1, CFTR, and CD163 in some BMI1⁺LGR5⁺ZSCAN4^{+&-} cells in ducts and interstitium between acini

Both aquaporin 1 water channel (AQP1) and cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel are expressed at the plasma membrane of human pancreatic ducts and can be used as markers for mature pancreatic duct cells (FIG. 4A and FIG. 10A) (Ko *et al.*, *Gastroenterology* 138:1988-1996, 2010). In contrast to the cells in the islets and acini, a small number of BMI1⁺LGR5⁺ZSCAN4^{+&-} cells located in the pancreatic ducts were also positive for AQP1 (FIG. 4A and FIGS. 4D-4G). It was also found that the pancreatic stellate cells were positive for AQP1, but not for CFTR (FIGS. 4B and 4C). On the other hand, pancreatic oval cells were positive for both AQP1 and CFTR (FIG. 4C and FIGS. 10B and 10C). Most of the pancreatic oval cells as well as the pancreatic stellate cells were positive for the hematopoietic stem cell marker CD163 (FIG. 4L). It has been speculated that there is a connection between the pancreatic stellate cells and hematopoietic stem cells (Sparmann *et al.*, *Cell Res* 20:288-298, 2010). Furthermore, some CD163⁺ cells were also found in (FIG. 4M) and around pancreatic ducts, especially in the basal membrane near some pancreatic ducts (FIG. 4N). Immunohistochemical analyses are summarized in Table 2.

Table 2: Summary of immunohistochemical analyses

Locations	Cell types	BMI1	LGR5	ZSCAN4	Pancreatic hormones	Amylase	AQP1	CFTR
Islet of Langerhans	BMI1 ⁺ LGR5 ⁺ ZSCAN4 ^{+&-} cells	+	+	+&-	-	-	-	-
	Other cells	-	-	-	+	-	-	-
Acinar	BMI1 ⁺ LGR5 ⁺ ZSCAN4 ^{+&-} cells	+	+	+&-	-	-	-	-
	Other cells	-	-	-	-	+	-	-
Duct	BMI1 ⁺ LGR5 ⁺ ZSCAN4 ^{+&-} cells	+	+	+&-	-	-	+	+
	Other cells	-	-	-	-	-	+	+
Other	Pancreatic oval cells	+	+	+&-	-	-	+	+
	Pancreatic stellate cells	-	-	-	-	-	+	-

Increase of ZSCAN4⁺ cells in chronic pancreatitis

Next, ZSCAN4 expression was examined in the pancreatic tissues that were recovered from chronic inflammation after treating patients with corticosteroid hormone for three months (Ko *et al.*, *Gastroenterology* 138:1988-1996, 2010). Compared to
5 pancreatic tissues from an unaffected individual (FIG. 5A), a dramatic increase of the ZSCAN4⁺ was observed in tissues under chronic inflammation: chronic alcoholic pancreatitis (FIG. 5B) and autoimmune pancreatitis (FIGS. 5C and 5D). Further increase of ZSCAN4⁺ cells was observed in the pancreatic tissues regenerated after three-month corticosteroid treatment (FIG. 5E). As noted earlier, in the normal human
10 pancreas, ZSCAN4⁺ cells were very rare and rather difficult to spot (FIG. 5A); however, in the regenerated tissues ZSCAN4⁺ cells were abundantly present (FIG. 5E). These ZSCAN4⁺ cells disappeared and returned to a normal level one year after the treatment (FIG. 5F). These data indicate that the inflammation and regeneration of pancreatic tissues are accompanied with the increase of ZSCAN4⁺ cells, suggesting the
15 involvement of ZSCAN4⁺ cells in the tissue regeneration.

Discussion

The immunohistochemistry analyses described above identified rare cells marked by the strong expression of ZSCAN4 as well as LGR5 and BMI1 in some of the
20 islets, acini, ducts, and the interstitium between acini. These data indicate that these rare cells are tissue stem/progenitor cells in the adult human pancreas based on several lines of evidence.

First, coexpression of stem cell marker genes (ZSCAN4, LGR5, and BMI1) in these cells provides strong indication that these cells, though rare, are real and possess
25 stem cell characters. Their infrequent presence in the pancreatic tissues is also consistent with the notion that the pancreas is an organ that does not have active tissue turnover/regeneration (Barker and Clevers, *Gastroenterology* 138:1681-1696, 2010). Furthermore, consistent with the strong expression of mouse Zscan4 in only about 5%

of undifferentiated mouse ES cells at a given time (Zalzman *et al.*, *Nature* 464:858-863, 2010), less than 10% of LGR5 positive cells are positive for ZSCAN4. This strong and unique pattern of ZSCAN4 expression in pancreas suggests the presence of functions similar to ES cells, i.e., a unique mechanism to maintain telomeres and genome stability in pancreas. The present disclosure provides the first demonstration of ZSCAN4 expression in human tissues and adult tissues/organs, as the inventors' previous study has shown the expression of mouse Zscan4 only in 2-cell embryos and a subpopulation of undifferentiated mouse ES cells (Falco *et al.*, *Dev Biol* 307:539-550, 2007).

Second, the lack of differentiation markers, such as amylase and pancreatic hormones, in the BMI1⁺LGR5⁺ZSCAN4^{+&-} cells located among other differentiated cells in acini and islets strongly suggests that these cells are undifferentiated stem/progenitor cells. By contrast, BMI1⁺LGR5⁺ZSCAN4^{+&-} cells located in the pancreatic duct express AQP1 and CFTR, which are genes indicative of differentiation. This specific feature of BMI1⁺LGR5⁺ZSCAN4^{+&-} cells located in the duct may be related to the fact that the duct cells are often singled out as potential stem/progenitor cells in pancreas (Bonner-Weir *et al.*, *Pediatr Diabetes* 5 Suppl 2:16-22, 2004).

Third, the number of ZSCAN4⁺ cells dramatically increases in the pancreatic tissues being regenerated after corticosteroid therapy from the massive ablation of pancreatic acini due to the chronic inflammation, which is followed by the precipitous decrease to the normal level a year after the treatment. This suggests either the increase of ZSCAN4⁺ tissue stem cell pools during pancreatic regeneration or the continued presence of ZSCAN4 proteins in the cells immediately after differentiation from ZSCAN4⁺ putative tissue stem cells. Observation of the significant increase of ZSCAN4⁺ in chronic pancreatitis suggests the role of pancreatic stem/progenitor cells in regeneration of pancreatic parenchyma by immunosuppressive therapy on inflammation.

Fourth, BMI1⁺LGR5⁺ZSCAN4^{+&-} cells are also located between adjacent pancreatic acini or around pancreatic ducts. Based on their location and the expression

of AQP1 and hematopoietic stem cell marker CD163, these oval-shaped BMI1⁺LGR5⁺ZSCAN4⁺&- cells may be related to the pancreatic stellate cells (Apte *et al.*, *Gut* 43:128-133, 1998), which are thought to be involved in pancreas fibrosis on chronic inflammation (Masamune *et al.*, *Clin Gastroenterol Hepatol* 7:S48-54, 2009) and at least some of which are thought to be bone marrow derived stem/progenitor cells (Sparmann *et al.*, *Cell Res* 20:288-298, 2010; Marrache *et al.*, *Gut* 57:1113-1120, 2008). Recent demonstration that some of the pancreatic stellate cells are progenitor cells that can produce β like cells (Mato *et al.*, *Biochem J* 421:181-191, 2009) may suggest that these cells are overlapped with the oval-shaped BMI1⁺LGR5⁺ZSCAN4⁺&- cells located in the place for the pancreatic stellate cells.

Type 1 diabetes and a subset of type 2 diabetes occur when there is an inadequate functional mass of insulin-producing pancreatic β cells. Diabetes could be cured if it were possible to find a way to obtain enough β cells for cell replacement therapy. Although cadaver islets, human ES cells, and induced pluripotent stem (iPS) cells are believed to be good candidates for the source of β cells for transplantation (Bonner-Weir and Weir, *Nat Biotechnol* 23:857-861, 2005), there are major obstacles to overcome before successful β cell replacement therapy is available. The pancreatic stem/progenitor cells disclosed herein could serve as a new source of differentiated β cells, as it is possible to obtain small pieces of pancreatic tissues by ultrasound guided TRU-CUTTM biopsy (Mizuno *et al.*, *J Gastroenterol* 44:742-750, 2009).

Example 3: Co-expression of ZSCAN4 and stem cell marker SSEA3

Caerulein-induced experimental pancreatitis has been widely used as a model for pancreatitis. Expression patterns of ZSCAN4 and other markers, including stage-specific embryonic antigen-3 (SSEA3), a carbohydrate epitope and a known stem cell marker, were examined in pancreatic tissues undergoing pancreatitis.

Immunohistochemical staining was performed to evaluate expression of Zscan4, SSEA3, LGR5 and BMI1. As shown in FIG. 11, SSEA3 exhibits a similar (but not

identical) expression pattern as Zscan4. Thus, these results indicate that SSEA3 can be used in some instances as a marker for ZSCAN4-expressing cells and/or as a means of enriching ZSCAN4⁺ cells.

5 In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit
10 of these claims.

CLAIMS

1. A method of isolating pancreatic stem cells or pancreatic progenitor cells, or both, from a sample comprising pancreatic tissue, the method comprising:
 - 5 (i) detecting expression of ZSCAN4 in cells of the sample; and
 - (ii) isolating the cells that express ZSCAN4, thereby isolating pancreatic stem cells or pancreatic progenitor cells, or both, from the sample.
2. The method of claim 1, wherein detecting expression of ZSCAN4
10 comprises detecting expression of a gene that is co-expressed with ZSCAN4.
3. The method of claim 2, wherein the gene that is co-expressed with ZSCAN4 is SSEA3 or Tcstv1/3.
- 15 4. The method of any one of claims 1-3, wherein detecting expression of ZSCAN4 comprises contacting the sample with an antibody specific for a protein encoded by ZSCAN4 or an antibody specific for a protein encoded by a gene co-expressed with ZSCAN4.
- 20 5. The method of claim 4, wherein the antibody is specific for a protein encoded by ZSCAN4.
6. The method of claim 4, wherein the antibody is specific for a protein encoded by SSEA3.
- 25 7. The method of claim 4, wherein the antibody is specific for a protein encoded by Tcstv1/3.

8. The method of claim 1, wherein detecting expression of ZSCAN4 comprises transfecting the cells of the sample with a vector comprising a ZSCAN4 promoter operably linked to a reporter gene or a selectable marker.

5 9. The method of claim 8, wherein the ZSCAN4 promoter is a mouse Zscan4c promoter.

10 10. The method of claim 9, wherein the Zscan4c promoter comprises the nucleic acid sequence set forth as nucleotides 906-4468 of SEQ ID NO: 15.

11. The method of any one of claims 8-10, wherein the reporter gene encodes a fluorescent protein.

15 12. The method of claim 11, wherein the fluorescent protein is a green fluorescent protein, or a variant thereof.

13. The method of any one of claims 8-12, wherein the vector comprises the nucleic acid sequence set forth as SEQ ID NO: 15.

20 14. The method of any one of claims 8-10, wherein the selectable marker is an antibiotic resistance gene.

25 15. The method of claim 14, wherein the antibiotic resistance gene is a puromycin-resistance gene.

16. The method of any one of claims 1-15, wherein the sample comprises human pancreatic tissue obtained by biopsy.

17. The method of any one of claims 1-16, wherein the method further comprises detecting expression of LGR5 or BMI1, or both, in cells of the sample, and isolating cells that also express LGR5 or BMI1, or both.

- 5 18. A method of treating diabetes in a subject, comprising:
- (i) isolating pancreatic stem cells or pancreatic progenitor cells wherein isolating the pancreatic stem cells or progenitor cells comprises detecting cells in pancreatic tissue that express ZSCAN4;
 - (ii) expanding the isolated pancreatic stem cells or progenitor cells
 - 10 that express ZSCAN4 *in vitro*; and
 - (iii) transplanting the expanded pancreatic stem cells or progenitor cells into the subject, thereby treating diabetes in a subject.

19. The method of claim 18, wherein the pancreatic stem cells or progenitor
15 cells of step (i) are isolated from the subject to be treated.

20. The method of claim 18 or claim 19, further comprising differentiating the pancreatic stem cells or progenitor cells into pancreatic β cells before transplanting the cells into the subject.
20

21. An *in vivo* method of expanding a population of pancreatic stem cells or progenitor cells in a subject, comprising delivering to the pancreas of the subject:
- (i) a ZSCAN4 protein;
 - (ii) a ZSCAN4 nucleic acid sequence; or
 - 25 (iii) an agent that increases expression of ZSCAN4 or increases the number of ZSCAN4⁺ cells, thereby expanding the population of pancreatic stem cells or progenitor cells in the subject.

22. The method of claim 21, wherein the ZSCAN4 protein comprises the amino acid sequence of SEQ ID NO: 2.

23. The method of claim 21 or claim 22, wherein delivery of the ZSCAN4
5 protein comprises administration of a ZSCAN4 protein encapsulated by a nanoparticle.

24. The method of claim 21, wherein the ZSCAN4 nucleic acid sequence comprises the nucleotide sequence of SEQ ID NO: 1.

10 25. The method of claim 21 or claim 24, wherein delivery of the ZSCAN4 nucleic acid sequence comprises administration of a vector comprises the ZSCAN4 nucleic acid sequence.

26. The method of claim 21, wherein the agent that increases expression of
15 ZSCAN4 is a retinoid.

FIG. 1





FIG. 2



3/11

FIG. 3





FIG. 4



5/11

FIG. 5




FIG. 6





FIG. 7



8/11

FIG. 8




FIG. 9




FIG.
10





FIG.
11



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/22575

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C12N 5/095; G01N 33/50 (2012.01)

USPC - 435/366; 436/63

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): C12N 5/095; G01N 33/50 (2012.01)

USPC: 435/366; 436/63

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC: 435/363; Biochem and Biophysical Research Communication. 2002, Vol 296; Nature. 2010, Vol 464; Nucleic Acids Research, 2006, Vol. 34

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST (PGPB,USPT,EPAB,JPAB); Google Web; Google Scholar; esp@cenet; NCBI: ZSCAN4, ZNF494, FLJ35105, zinc finger, SCAN, domain, pancreas, stem, progenitor, beta, retinoid, nanoparticle, Zscan4c; wipo, retinoic acid, puromycin, promoter, Minoru Ko, Shigeru Ko,

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y — A	WO 2008/118957 A2 (KO et al.) 2 October 2008 (02.10.2008), pg 3, ln 12-16; pg 5, ln 23-24; pg 26, ln 9-14; pg 33, ln 17-30; pg 35, ln 2-5; pg 41, ln 1-2; pg 41, ln 10-14; pg 41, ln 17-19;	1-12, 14, 15, 18-26 10
Y — A	US 2006/0251642 A1 (WOLFFE et al.) 9 November 2006 (09.11.2006), abstract; para [0184].	1-12, 14, 15, 18-26 10
Y — A	PI et al. A novel human SCAN/(Cys)2(His)2 zinc-finger transcription factor ZNF323 in early human embryonic development. Biochem and Biophysical Research Communication. 2002, Vol 296, Pages 206-213, especially pg 206, abstract.	1-12, 14, 15, 18-26 10
Y	ZALZMAN et al. Zscan4 regulates telomere elongation and genomic stability in ES cells. Nature. 2010, Vol 464, Pages 858-863, especially pg 858, abstract; pg 862, col 1, para 4	15
Y	US 2005/0277190 A1 (SEABERG et al.) 15 December 2005 (15.12.2005), abstract; para [0015], [0016], [0017], [0019], [0025], [0066], [0073], [0085], [0129].	18-26
Y	US 2004/0058457 A1 (HUANG et al.) 25 March 2004 (25.03.2004), abstract; claim 23; claim 25.	23

☒ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

16 April 2012 (16.04.2012)

Date of mailing of the international search report

29 MAY 2012

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/22575

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 13, 16, 17
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 12/22575

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ZHANG et al. Zfp206 regulates ES cell gene expression and differentiation. Nucleic Acids Research, 2006, Vol. 34, Pages 4780-4790, especially page 4780, abstract; pg 4782, col 2, para 2.	26
X,P	WO 2011/028880 A2 (KO et al.) 10 March 2011 (10.03.2011), abstract	1, 8, 9, 10